Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof

Abstract

To provide a bispecific antigen-binding molecule that binds to both CD3 and target antigen.SOLUTION: An antibody of the present invention binds to human CD3 at high affinity, and induces human T cell proliferation. The present invention includes an antibody that binds to CD3, and induces T cell-mediated killing of a tumor cell. According to a specific embodiment, the present invention provides a bispecific antigen-binding molecule including a first antigen-binding domain which specifically binds to human CD3, and a second antigen-binding molecule which specifically binds to human CD20. In a specific embodiment, the bispecific antigen-binding molecule of the present invention can inhibit proliferation of a B cellular tumor expressing CD20. The antibody and the bispecific antigen-binding molecule of the present invention are useful for treating diseases and disorders for which upregulated or induced targeted immune response is desirable and / or therapeutically beneficial. For example, the antibody of the present invention is useful for treating various kinds of cancer, and furthermore useful for treating other CD20-related diseases and disorders.SELECTED DRAWING: None

Description

[Technical Field]

[0001] FIELD OF THE INVENTION The present invention relates to antibodies specific for CD3, and antigen-binding fragments thereof, and methods of using them. The present invention also relates to bispecific antigen-binding molecules that bind to CD3 and target molecules such as CD20, and methods of using them. [Background technology]

[0002] background CD3 is a homodimeric or heterodimeric antigen expressed on T cells in association with the T cell receptor complex (TCR) and is required for T cell activation. Functional CD3 is formed by the dimeric association of two of four distinct chains: epsilon, zeta, delta, and gamma. CD3 dimer configurations include gamma / epsilon, delta / epsilon, and zeta / zeta. Antibodies against CD3 have been shown to cluster CD3 on T cells, thereby triggering T cell activation in a manner similar to TCR engagement with peptide-loaded MHC molecules. Therefore, anti-CD3 antibodies have been proposed for therapeutic purposes, including T cell activation. Furthermore, bispecific antibodies capable of binding to CD3 and a target antigen have been proposed for therapeutic uses, including targeting T cell immune responses to tissues and cells expressing the target antigen.

[0003] CD20 is a nonglycosylated, phosphorylated protein expressed on the plasma membrane of mature B cells. CD20 is considered a B cell tumor-associated antigen because it is expressed in more than 95% of B cell non-Hodgkin's lymphoma (NHL) and other B cell malignancies but is absent from B precursor cells, dendritic cells, and plasma cells. Methods for treating cancer by targeting CD20 are known in the art. For example, the chimeric anti-CD20 monoclonal antibody rituximab has been used or proposed for use in treating cancers such as NHL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). CD20 is believed to kill CD20-expressing tumor cells by inducing complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and / or apoptosis and sensitization to chemotherapy. Although anti-CD20 tumor targeting strategies have shown great promise in the clinical setting, not all patients respond to anti-CD20 therapy, and some patients develop resistance to or show an incomplete response to anti-CD20 therapy (e.g., resistance to rituximab). Summary of the Invention [Problem to be solved by the invention]

[0004] Bispecific antigen binding molecules that bind to both CD3 and a target antigen (e.g., CD20) may be useful in therapeutic settings where specific targeting and T cell-mediated killing of cells expressing the target antigen is desirable. [Means for solving the problem]

[0005] Summary of the Invention In a first aspect, the present invention provides antibodies and antigen-binding fragments thereof that bind to human CD3. Antibodies according to this aspect of the invention are useful, inter alia, for targeting CD3-expressing T cells and stimulating T cell activation, e.g., in situations where T cell-mediated killing is beneficial or desirable. The anti-CD3 antibodies of the invention, or antigen-binding portions thereof, bind to CD3-mediated T cells. The antibody may be included as part of a bispecific antibody that directs mediated T cell activation to a specific cell type, such as a tumor cell or an infectious agent.

[0006] Exemplary anti-CD3 antibodies of the present invention are listed in Tables 1 and 2 herein. Table 1 provides amino acid sequence identifiers for the heavy chain variable regions (HCVRs) and light chain variable regions (LCVRs), as well as the heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), and light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) of exemplary anti-CD3 antibodies. Table 2 provides sequence identifiers for nucleic acid molecules encoding the HCVRs, LCVRs, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of exemplary anti-CD3 antibodies.

[0007] The present invention provides antibodies, or antigen-binding fragments thereof, comprising an HCVR comprising an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0008] The present invention also provides an antibody, or antigen-binding fragment thereof, comprising an LCVR comprising an amino acid sequence selected from any of the LCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0009] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising an HCVR and LCVR amino acid sequence pair (HCVR / LCVR) comprising any of the HCVR amino acid sequences listed in Table 1 paired with any of the LCVR amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides antibodies, or antigen-binding fragments thereof, comprising an HCVR / LCVR amino acid sequence pair contained within any of the exemplary anti-CD3 antibodies listed in Table 1. In certain embodiments, the HCVR / LCVR amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 2 / 10 (e.g., H1H2712N); 114 / 122 (e.g., H2M2609N); 514 / 522 (e.g., H2M3563N); 770 / 778 (e.g., H1H5778P); 1050 / 1234 (e.g., H1H7195B); and 1090 / 1234 (e.g., H1H7208B).

[0010] The present invention also provides an antibody, or an antigen-binding fragment thereof, comprising a heavy chain CDR1 (HCDR1) comprising an amino acid sequence selected from any of the HCDR1 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0011] The present invention also provides an antibody or antigen-binding fragment thereof comprising a heavy chain CDR2 (HCDR2) comprising an amino acid sequence selected from any of the HCDR2 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0012] The present invention also provides an antibody, or an antigen-binding fragment thereof, comprising a heavy chain CDR3 (HCDR3) comprising an amino acid sequence selected from any of the HCDR3 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0013] The present invention also provides an antibody, or an antigen-binding fragment thereof, comprising a light chain CDR1 (LCDR1) comprising an amino acid sequence selected from any of the LCDR1 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0014] The present invention also provides an antibody, or an antigen-binding fragment thereof, comprising a light chain CDR2 (LCDR2) comprising an amino acid sequence selected from any of the LCDR2 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0015] The present invention also provides an antibody, or an antigen-binding fragment thereof, comprising a light chain CDR3 (LCDR3) comprising an amino acid sequence selected from any of the LCDR3 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0016] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising an HCDR3 and LCDR3 amino acid sequence pair (HCDR3 / LCDR3) comprising any of the HCDR3 amino acid sequences listed in Table 1 paired with any of the LCDR3 amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides antibodies, or antigen-binding fragments thereof, comprising an HCDR3 / LCDR3 amino acid sequence pair contained within any of the exemplary anti-CD3 antibodies listed in Table 1. In certain embodiments, the HCDR3 / LCDR3 amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 8 / 16 (e.g., H1H2712N); 120 / 128 (e.g., H2M2609N); 520 / 528 (e.g., H2M3563N); 776 / 784 (e.g., H1H5778P); 1056 / 1240 (e.g., H1H7195B); and 1096 / 1240 (e.g., H1H7208B).

[0017] The present invention also provides antibodies, or antigen-binding fragments thereof, comprising six CDR sets (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within any of the exemplary anti-CD3 antibodies listed in Table 1. In certain embodiments, the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence sets are set forth in SEQ ID NOs: 4-6-8-12-14-16 (e.g., H1H2712N); 116-118-120-124-126-128 (e.g., H2M2609N); 516-518-520-524-526-528 (e.g., H3M2609N); For example, selected from the group consisting of: H2M3563N); 772-774-776-780-782-784 (e.g., H1H5778P); 1052-1054-1056-1236-1238-1240 (e.g., H1H7195B); and 1092-1094-1096-1236-1238-1240 (e.g., H1H7208B).

[0018] In related embodiments, the invention provides antibodies, or antigen-binding fragments thereof, that comprise a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within the HCVR / LCVR amino acid sequence pair defined by any of the exemplary anti-CD3 antibodies listed in Table 1. For example, the invention includes antibodies, or antigen-binding fragments thereof, that comprise a set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences contained within the HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10 (e.g., H1H2712N); 114 / 122 (e.g., H2M2609N); 514 / 522 (e.g., H2M3563N); 770 / 778 (e.g., H1H5778P); 1050 / 1234 (e.g., H1H7195B); and 1090 / 1234 (e.g., H1H7208B). Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs within the particular HCVR and / or LCVR amino acid sequences disclosed herein. Exemplary conventions that can be used to identify CDR boundaries include, for example, the Kabat definition, the Chothia definition, and the AbM definition. Broadly speaking, the Kabat definition is based on sequence variability, the Chothia definition is based on the location of structural loop regions, and the AbM definition is based on the Kabat approach. The method is a compromise between the Roche and Chothia approaches. See, e.g., Kabat, "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J. Mol. Biol. 273:927-948 (1997); and Martin et al., Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989). Public databases are also available for identifying CDR sequences within antibodies.

[0019] The present invention also provides nucleic acid molecules encoding anti-CD3 antibodies or portions thereof. For example, the present invention provides nucleic acid molecules encoding any of the HCVR amino acid sequences listed in Table 1; in specific embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0020] The present invention also provides nucleic acid molecules encoding any of the LCVR amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0021] The present invention also provides a nucleic acid molecule encoding any of the HCDR1 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0022] The present invention also provides nucleic acid molecules encoding any of the HCDR2 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0023] The present invention also provides nucleic acid molecules encoding any of the HCDR3 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0024] The present invention also provides a nucleic acid molecule encoding any of the LCDR1 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0025] The present invention also provides nucleic acid molecules encoding any of the LCDR2 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule is selected from any of the LCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto. The polynucleotide sequence includes a polynucleotide sequence that is

[0026] The present invention also provides nucleic acid molecules encoding any of the LCDR3 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0027] The present invention also provides nucleic acid molecules encoding HCVRs, wherein the HCVRs comprise a set of three CDRs (i.e., HCDR1-HCDR2-HCDR3), wherein the HCDR1-HCDR2-HCDR3 amino acid sequence set is as defined by any of the exemplary anti-CD3 antibodies listed in Table 1.

[0028] The present invention also provides nucleic acid molecules encoding LCVRs, wherein the LCVRs comprise a set of three CDRs (i.e., LCDR1-LCDR2-LCDR3), wherein the LCDR1-LCDR2-LCDR3 amino acid sequence set is as defined by any of the exemplary anti-CD3 antibodies listed in Table 1.

[0029] The present invention also provides nucleic acid molecules encoding both an HCVR and an LCVR, wherein the HCVR comprises the amino acid sequence of any of the HCVR amino acid sequences listed in Table 1, and the LCVR comprises the amino acid sequence of any of the LCVR amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto, and a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto. In certain embodiments, according to this aspect of the invention, the nucleic acid molecule encodes an HCVR and an LCVR, wherein the HCVR and LCVR are both from the same anti-CD3 antibody listed in Table 1.

[0030] The present invention also provides recombinant expression vectors capable of expressing polypeptides comprising the heavy and light chain variable regions of an anti-CD3 antibody. For example, the present invention includes recombinant expression vectors comprising any of the nucleic acid molecules described above, i.e., any of the HCVR, LCVR, and / or CDR sequences set forth in Table 1. Also included within the scope of the present invention are host cells into which such vectors have been introduced, as well as methods for producing antibodies or portions thereof by culturing the host cells under conditions that permit the production of the antibody or antibody fragment, and recovering the antibody and antibody fragment so produced.

[0031] The present invention includes anti-CD3 antibodies with altered glycosylation patterns. In some embodiments, modifications to remove undesired glycosylation sites or antibodies lacking fucose moieties present on the oligosaccharide chains may be useful, for example, to increase antibody-dependent cellular cytotoxicity (ADCC) function (see Shield et al. (2002) JBC 277:26733). In other applications, galactosylation modifications may be performed to alter complement-dependent cytotoxicity (CDC).

[0032] In another aspect, the invention provides a pharmaceutical composition comprising a recombinant human antibody or fragment thereof that specifically binds to CD3 and a pharmaceutically acceptable carrier. In a related aspect, the invention features a composition that is a combination of an anti-CD3 antibody and a second therapeutic agent. In one embodiment, the second therapeutic agent is any agent that is advantageously combined with the anti-CD3 antibody. These agents are exemplary agents that may be advantageously combined with anti-CD3 antibodies. Exemplary agents that may be advantageously combined with anti-CD3 antibodies include, without limitation, other agents that bind to and / or activate CD3 signaling (including other antibodies or antigen-binding fragments thereof, etc.) and / or agents that activate or stimulate immune cell activation without directly binding to CD3. Additional combination therapies and co-formulations comprising the anti-CD3 antibodies of the invention are disclosed elsewhere herein.

[0033] In yet another aspect, the invention provides therapeutic methods for stimulating T cell activation using an anti-CD3 antibody or an antigen-binding portion of an antibody of the invention, wherein the therapeutic method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an antibody or antigen-binding fragment of the antibody of the invention. The disorder to be treated is any disease or condition that is ameliorated, ameliorated, inhibited, or prevented by stimulation of CD3 activity or signaling.

[0034] According to another aspect, the present invention provides bispecific antigen-binding molecules that bind to CD3 and a target antigen. According to certain exemplary embodiments, the bispecific antigen-binding molecules bind to both CD3 and CD20; such bispecific antigen-binding molecules are also referred to herein as "anti-CD3 / anti-CD20 bispecific molecules." The anti-CD20 portion of the anti-CD3 / anti-CD20 bispecific molecule is useful for targeting tumor cells that express CD20 (e.g., B-cell tumors), and the anti-CD3 portion of the bispecific molecule is useful for activating T cells. The simultaneous binding of CD20 on tumor cells and CD3 on T cells promotes directed killing (cytolysis) of the target tumor cells by activated T cells. Thus, the anti-CD3 / anti-CD20 bispecific molecules of the present invention are useful for treating diseases and disorders associated with or caused by CD20-expressing tumors (e.g., lymphomas), among others.

[0035] Bispecific antigen-binding molecules according to this aspect of the invention comprise a first antigen-binding domain that specifically binds to human CD3 and a second antigen-binding domain that specifically binds to CD20. The invention includes anti-CD3 / anti-CD20 bispecific molecules (e.g., bispecific antibodies) in which each antigen-binding domain comprises a heavy chain variable region (HCVR) paired with a light chain variable region (LCVR). In certain exemplary embodiments of the invention, the anti-CD3 antigen-binding domain and the anti-CD20 antigen-binding domain each comprise a different, individual HCVR paired with a common LCVR. For example, as described in Example 7 herein, a bispecific antibody was constructed that comprises a first antigen-binding domain that specifically binds to CD3 (wherein the first antigen-binding domain comprises an HCVR / LCVR pair from anti-CD3); and a second antigen-binding domain that specifically binds to CD20 (wherein the second antigen-binding domain comprises an HCVR from an anti-CD20 antibody paired with an LCVR from an anti-CD3 antibody (e.g., the same LCVR contained in the anti-CD3 antigen-binding domain). In other words, in the exemplary molecules disclosed herein, pairing of a HCVR from an anti-CD20 antibody with a LCVR from an anti-CD3 antibody results in an antigen-binding domain that specifically binds CD20 (but does not bind CD3). In such embodiments, the first and second antigen-binding domains comprise distinct anti-CD3 and anti-CD20 HCVRs but share a common anti-CD3 LCVR.

[0036] The present invention provides anti-CD3 / anti-CD20 bispecific molecules, wherein a first antigen-binding domain that specifically binds to CD3 comprises any of the HCVR amino acid sequences shown in Table 1 or Table 18. The first antigen-binding domain that specifically binds to CD3 may also comprise any of the LCVR amino acid sequences shown in Table 1 or Table 19. According to certain embodiments, the first antigen-binding domain that specifically binds to CD3 comprises any of the HCVR / LCVR amino acid sequence pairs shown in Table 1 or Table 17. The present invention also provides anti-CD3 / anti-CD20 bispecific molecules, wherein a first antigen-binding domain that specifically binds to CD3 comprises any of the heavy chain CDR1-CDR2-CDR3 amino acid sequences shown in Table 1 or Table 18 and / or any of the light chain CDR1-CDR2-CDR3 amino acid sequences shown in Table 1 or Table 19. do.

[0037] According to certain embodiments, the present invention provides anti-CD3 / anti-CD20 bispecific molecules, wherein the first antigen-binding domain that specifically binds to CD3 comprises a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1250, 1266, 1282, 1298, 1314 and 1329, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0038] The present invention also provides anti-CD3 / anti-CD20 bispecific molecules, wherein a first antigen-binding domain that specifically binds to CD3 comprises a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1258, 1274, 1290, 1306, 1322 and 1333, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0039] The present invention also provides anti-CD3 / anti-CD20 bispecific molecules, wherein a first antigen-binding domain that specifically binds to CD3 comprises a HCVR and LCVR (HCVR / LCVR) amino acid sequence pair selected from the group consisting of SEQ ID NOs: 1250 / 1258, 1266 / 1274, 1282 / 1290, 1298 / 1306, 1314 / 1322, and 1329 / 1333.

[0040] The present invention also provides anti-CD3 / anti-CD20 bispecific molecules, wherein the first antigen-binding domain that specifically binds to CD3 comprises a heavy chain CDR3 (HCDR3) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1256, 1272, 1288, 1304, 1320, and 1332, or a sequence substantially similar thereto with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity; and a light chain CDR3 (LCDR3) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328, and 1336, or a sequence substantially similar thereto with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0041] In certain embodiments, the first antigen-binding domain that specifically binds to CD3 comprises an HCDR3 / LCDR3 amino acid sequence pair selected from the group consisting of SEQ ID NOs: 1256 / 1264, 1272 / 1280, 1288 / 1296, 1304 / 1312, 1320 / 1328 and 1332 / 1336.

[0042] The present invention also provides a method for identifying a first antigen-binding domain that specifically binds to CD3, comprising: a heavy chain CDR1 (HCDR1) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1252, 1268, 1284, 1300, 1316, and 1330, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity; a heavy chain CDR2 (HCDR2) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1254, 1270, 1286, 1302, 1318, and 1331, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity; a light chain CDR1 (LCDR1) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324, and 1334, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity; and a light chain CDR2 (LCDR2) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326, and 1335, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity. The original binding molecule is provided.

[0043] Specific, non-limiting exemplary anti-CD3 / anti-CD20 bispecific antigen binding molecules of the present invention are represented by SEQ ID NOs: 1252-1254-1256-1260-1262-1264 (e.g., BS3 / 20-001); 1268-1270-1272-1276-1278-1280 (e.g., BS3 / 20-002); 1284-1286-1288-1292-1294-1296 (e.g., BS3 / 20-003); 1300-1302-1304-1308-1309 (e.g., BS3 / 20-004); and 1330-1331-1332-1334-1335-1336 (e.g., BS3 / 20-007).

[0044] The present invention also provides anti-CD3 / anti-CD20 bispecific molecules, wherein the second antigen-binding domain that specifically binds to CD20 comprises a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO: 1242, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0045] The present invention also provides anti-CD3 / anti-CD20 bispecific molecules, wherein the second antigen-binding domain that specifically binds to CD20 comprises a light chain variable region (LCVR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1258, 1274, 1290, 1306, 1322 and 1333, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

[0046] The present invention also provides anti-CD3 / anti-CD20 bispecific molecules, wherein the second antigen-binding domain that specifically binds to CD20 comprises a HCVR and LCVR (HCVR / LCVR) amino acid sequence pair selected from the group consisting of SEQ ID NOs: 1242 / 1258, 1242 / 1274, 1242 / 1290, 1242 / 1306, 1242 / 1322, and 1242 / 1333.

[0047] The present invention also provides anti-CD3 / anti-CD20 bispecific molecules, wherein the second antigen-binding domain that specifically binds to CD20 comprises a heavy chain CDR3 (HCDR3) domain having the amino acid sequence of SEQ ID NO: 1248, or a sequence substantially similar thereto with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity; and a light chain CDR3 (LCDR3) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1264, 1280, 1296, 1312, 1328, and 1336, or a sequence substantially similar thereto with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0048] In certain embodiments, the second antigen-binding domain that specifically binds to CD20 comprises an HCDR3 / LCDR3 amino acid sequence pair selected from the group consisting of SEQ ID NOs: 1248 / 1264, 1248 / 1280, 1248 / 1296, 1248 / 1312, 1248 / 1328, and 1248 / 1336.

[0049] The present invention also relates to a second antigen-binding domain that specifically binds to CD20, comprising a heavy chain CDR1 (HCDR1) domain having the amino acid sequence of SEQ ID NO: 1244, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity; an amino acid sequence of SEQ ID NO: 1246, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity; a heavy chain CDR2 (HCDR2) domain having a substantially similar sequence of SEQ ID NOs: 1260, 1276, 1292, 1308, 1324, and 1334, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity; and a light chain CDR2 (LCDR2) domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1262, 1278, 1294, 1310, 1326, and 1335, or a substantially similar sequence thereof with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0050] Specific, non-limiting exemplary anti-CD3 / anti-CD20 bispecific antigen binding molecules of the present invention are represented by SEQ ID NOs: 1244-1246-1248-1260-1262-1264 (e.g., BS3 / 20-001); 1244-1246-1248-1276-1278-1280 (e.g., BS3 / 20-002); 1244-1246-1248-1292-1294-1296 (e.g., BS3 / 20-003); 1244-1246-1248-1308-131 and a second antigen-binding domain that specifically binds to CD20, comprising an HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domain having an amino acid sequence selected from the group consisting of: 0-1312 (e.g., BS3 / 20-004); 1244-1246-1248-1324-1326-1328 (e.g., BS3-20-005); and 1244-1246-1248-1334-1335-1336 (e.g., BS3 / 20-007).

[0051] In a related embodiment, the invention comprises an anti-CD3 / anti-CD20 bispecific antigen-binding molecule, wherein the second antigen-binding domain that specifically binds to CD20 comprises heavy and light chain CDR domains contained within heavy and light chain variable region (HCVR / LCVR) sequences selected from the group consisting of SEQ ID NOs: 1242 / 1258, 1242 / 1274, 1242 / 1290, 1242 / 1306, 1242 / 1322 and 1242 / 1333.

[0052] In another aspect, the present invention provides nucleic acid molecules encoding any of the HCVR, LCVR, or CDR sequences of the anti-CD3 / anti-CD20 bispecific antigen-binding molecules disclosed herein, including nucleic acid molecules comprising the polynucleotide sequences set forth in Tables 20 and 21 herein, as well as nucleic acid molecules comprising two or more of the polynucleotide sequences set forth in Tables 20 and 21 in any functional combination or arrangement thereof. Recombinant expression vectors harboring nucleic acids of the invention and host cells into which such vectors have been introduced are also encompassed by the present invention, as are methods of producing antibodies by culturing these host cells under conditions that allow the production of the antibodies and recovering the antibodies produced.

[0053] The present invention includes anti-CD3 / anti-CD20 bispecific antigen-binding molecules in which any of the above-mentioned antigen-binding domains that specifically bind to CD3 are combined, connected, or otherwise associated with any of the above-mentioned antigen-binding domains that specifically bind to CD20 to form a bispecific antigen-binding molecule that binds to CD3 and CD20.

[0054] The present invention includes anti-CD3 / anti-CD20 bispecific antigen-binding molecules with altered glycosylation patterns. In some applications, modifications to remove undesired glycosylation sites may be useful, or antibodies lacking fucose moieties present on the oligosaccharide chains to increase antibody-dependent cellular cytotoxicity (ADCC) function (Shield et al., 2004). (See, e.g., JBC 277:26733) may be useful. In other applications, altered galactosylation may be performed to alter complement-dependent cytotoxicity (CDC).

[0055] In another aspect, the present invention provides a pharmaceutical composition comprising an anti-CD3 / anti-CD20 bispecific antigen-binding molecule disclosed herein and a pharmaceutically acceptable carrier. In a related aspect, the invention features a composition that is a combination of an anti-CD3 / anti-CD20 bispecific antigen-binding molecule and a second therapeutic agent. In one embodiment, the second therapeutic agent is any agent that can be advantageously combined with an anti-CD3 / anti-CD20 bispecific antigen-binding molecule. Exemplary agents that can be advantageously combined with an anti-CD3 / anti-CD20 bispecific antigen-binding molecule are discussed in detail elsewhere herein.

[0056] In yet another aspect, the present invention provides a therapeutic method for targeting / killing CD20-expressing tumor cells using the anti-CD3 / anti-CD20 bispecific antigen-binding molecule of the present invention, wherein the therapeutic method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the anti-CD3 / anti-CD20 bispecific antigen-binding molecule of the present invention.

[0057] The present invention also includes the use of an anti-CD3 / anti-CD20 bispecific antigen-binding molecule of the invention in the manufacture of a medicament for the treatment of a disease or disorder associated with or caused by CD20 expression.

[0058] Other embodiments will become apparent from consideration of the following detailed description. [Brief explanation of the drawings]

[0059] [Figure 1] Tumor volume (mm3) after tumor engraftment and treatment with either human Fc (hFc, solid line) or CD3xCD20 bispecific antibody (BS3 / 20-007, dotted line) in NOD / SCID mice implanted subcutaneously with a mixture of Raji tumor cells and PBMCs is shown over time, starting on the day of tumor engraftment. [Figure 2] Tumor volume (mm3) after tumor engraftment and treatment with either human Fc (hFc, solid line) or CD3xCD20 bispecific antibody (BS3 / 20-007, dotted line) in NOD / SCID mice implanted subcutaneously with a mixture of Raji tumor cells and PBMCs is shown over time, starting 7 days after tumor engraftment. [Figure 3] FIG. 1 shows a plot of B cell counts (×1000 / μL) over time in blood samples from cynomolgus monkeys treated with three different doses of bispecific antibody BS3 / 20-001 (0.01, 0.1, or 1.0 mg / kg); a low-dose anti-CD20 control antibody (Control V, 0.01 mg / kg); or a high-dose anti-CD20 control antibody (Control III (1.0 mg / kg)). [Figure 4] FIG. 1 shows a plot of T cell counts (×1000 / μL) over time in blood samples from cynomolgus monkeys treated with three different doses of bispecific antibody BS3 / 20-001 (0.01, 0.1, or 1.0 mg / kg); a low-dose anti-CD20 control antibody (Control V, 0.01 mg / kg); or a high-dose anti-CD20 control antibody (Control III (1.0 mg / kg)). [Figure 5-1] A-D show pre- and post-dose levels (pg / mL) of IFN-gamma, IL-2, IL-6, and TNF-alpha, respectively, for cynomolgus monkeys treated with a single dose of BS3 / 20-001 (0.01, 0.1, or 1.0 mg / kg), a low-dose anti-CD20 control antibody (0.01 mg / kg Control V), or a high-dose anti-CD20 control antibody (1.0 mg / kg Control III). [Figure 5-2] Continued from Figure 5-1. [Figure 5-3] Continued from Figure 5-2. [Figure 5-4] Continued from Figure 5-3. [Figure 6]1 shows CD20 expression profiles (expressed as Log2 fold change in expression) determined from blood samples taken at various time points from cynomolgus monkeys treated with 0.01 mg / kg control V (anti-CD20 antibody); 1.0 mg / kg control III (anti-CD20 antibody); and 0.01 mg / kg, 0.1 mg / kg, and 1.0 mg / kg BS3 / 20-001 (anti-CD3xCD20 bispecific antibody). [Figure 7] Figure 1 shows the total serum concentration (μg / mL) of CD3xCD20 bispecific antibody (BS3 / 20-001) over time in blood samples from cynomolgus monkeys treated with 1.0 mg / kg (open triangles), 0.1 mg / kg (open squares), or 0.01 mg / kg (open diamonds) of CD3xCD20 bispecific antibody. DETAILED DESCRIPTION OF THE INVENTION

[0060] Detailed Description Before describing the present invention, it is to be understood that this invention is not limited to the particular methods and experimental conditions described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0061] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. As used herein, the term "about," when used in connection with a specific stated value, means that the value may vary by 1% or less from the stated value. For example, the expression "about 100" used herein includes 99 and 101 and all values ​​therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0062] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.

[0063] definition As used herein, the phrase "CD3" refers to an antigen expressed on T cells as part of the multimolecular T cell receptor (TCR) and consisting of a homodimer or heterodimer formed by the combination of two of the four receptor chains: CD3-epsilon, CD3-delta, CD3-zeta, and CD3-gamma. Human CD3-epsilon comprises the amino acid sequence set forth in SEQ ID NO: 1370; human CD3-delta comprises the amino acid sequence set forth in SEQ ID NO: 1371. All references herein to proteins, polypeptides, and protein fragments are intended to refer to the human version of the respective protein, polypeptide, or protein fragment, unless specifically identified as being derived from a non-human species. Thus, the phrase "CD3" refers to human CD3 unless specifically identified as being derived from a non-human species, e.g., "mouse CD3," "monkey CD3," etc.

[0064] As used herein, "antibodies that bind CD3" or "anti-CD3 antibodies" include antibodies and antigen-binding fragments thereof that specifically recognize a single CD3 subunit (e.g., epsilon, delta, gamma, or zeta), as well as antibodies and antigen-binding fragments thereof that specifically recognize dimeric complexes of two CD3 subunits (e.g., gamma / epsilon, delta / epsilon, and zeta / zeta CD3 dimers). The antibodies and antigen-binding fragments of the invention can bind to soluble CD3 and / or CD3 expressed on the cell surface. Soluble CD3 includes native CD3 protein as well as recombinant CD3 protein variants that lack the transmembrane domain or are otherwise not bound to the cell membrane, such as, for example, monomeric and dimeric CD3 constructs.

[0065] As used herein, the phrase "cell surface-expressed CD3" refers to one or more CD3 proteins that are expressed on the surface of a cell in vitro or in vivo, such that at least a portion of the CD3 protein is exposed on the extracellular side of the cell membrane and is accessible to the antigen-binding portion of an antibody. "Cell surface-expressed CD3" refers to a functional CD3 protein at the membrane of a cell. The term "CD3 expressed on the cell surface" includes CD3 proteins contained within the context of the human T-cell receptor. The phrase "CD3 expressed on the cell surface" includes CD3 proteins expressed on the cell surface as part of homodimers or heterodimers (e.g., gamma / epsilon, delta / epsilon, and zeta / zeta CD3 dimers). The phrase "CD3 expressed on the cell surface" also includes CD3 chains expressed on the cell surface by themselves, without other CD3 chains (e.g., CD3-epsilon, CD3-delta, or CD3-gamma). "CD3 expressed on the cell surface" may comprise or consist of CD3 proteins expressed on the surface of cells that normally express CD3 proteins. Alternatively, "CD3 expressed on the cell surface" may comprise or consist of CD3 proteins expressed on the surface of cells that do not normally express human CD3 on their surface but have been artificially engineered to express CD3 on their surface.

[0066] As used herein, the phrase "anti-CD3 antibody" includes both monovalent antibodies having a single specificity, as well as bispecific antibodies comprising a first arm that binds to CD3 and a second arm that binds to a second (target) antigen, where the anti-CD3 arm comprises any of the HCVR / LCVR or CDR sequences set forth in Table 1 or Table 18 / 19 herein. Examples of anti-CD3 bispecific antibodies are described elsewhere herein. The term "antigen-binding molecule" includes antibodies and antigen-binding fragments, including, for example, bispecific antibodies.

[0067] As used herein, the term "antibody" refers to any antigen-binding molecule or molecular complex comprising at least one complementarity-determining region (CDR) that specifically binds to or interacts with a particular antigen (e.g., CD3). The term "antibody" includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM). Each heavy chain comprises a heavy chain variable region (herein referred to as HCVR or V H The heavy chain constant region comprises: Three Domains C H 1. C H 2 and C H Each light chain comprises a light chain variable region (referred to herein as a LCVR or V L The light chain constant region contains one domain, (C L 1) V H and V L The more conserved regions are called complementarity determining regions (CDRs). Each V can be further subdivided into regions of hypervariability embedded in regions called framework regions (FR). H and V L is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the present invention, the FRs of an anti-CD3 antibody (or antigen-binding portion thereof) may be the same as human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on side-by-side analysis of two or more CDRs.

[0068] As used herein, the term "antibody" also includes antigen-binding fragments of intact antibody molecules. As used herein, the terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like include naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptides or glycoproteins that specifically bind to an antigen to form a complex. Antigen-binding fragments of antibodies can be derived from intact antibody molecules using any suitable standard technique, such as proteolytic digestion or recombinant genetic engineering techniques, including the manipulation and expression of DNA encoding the variable and, optionally, constant domains of the antibody. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA can be sequenced and manipulated chemically or using molecular biology techniques, for example, to arrange one or more variable and / or constant domains into the appropriate configuration, or to introduce codons, generate cysteine ​​residues, modify, add, or delete amino acids, etc.

[0069] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues that mimic the hypervariable regions of an antibody (e.g., isolated complementarity-determining regions (CDRs) such as CDR3 peptides), or constrained FR3-CDR3-FR4 peptides. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains are also encompassed within the expression "antigen-binding fragment" as used herein.

[0070] Antigen-binding fragments of antibodies typically contain at least one variable domain, which may be of any size or amino acid composition and generally contains at least one CDR adjacent to or in-frame with one or more framework sequences. L V associated with the domain H In an antigen-binding fragment having a domain, V H and V L The domains can be positioned in any suitable arrangement relative to each other. For example, the variable region can be a dimer, with the V H -V H , V H -V L or V L -V L Alternatively, the antigen-binding fragment of an antibody may contain a dimer of monomeric V H or V L It may contain domains.

[0071] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found in an antigen-binding fragment of an antibody of the invention include: (i) V H -C H 1;(ii) V H -C H 2;(iii) V H -C H 3;(iv) V H -C H 1-C H 2;(v) V H -C H 1-C H 2-C H 3;(vi) V H -C H 2-C H 3;(vii) V H -C L ;(viii) V L -C H 1;(ix) V L -C H 2;(x) V L -C H 3;(xi) V L -C H 1-C H 2;(xi i) V L -C H 1-C H 2-C H 3;(xiii)V L -C H 2-C H 3; and (xiv) V L -C LIn any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. A hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that create a flexible or semi-flexible linkage between adjacent variable and / or constant domains in a single polypeptide molecule. Furthermore, antigen-binding fragments of antibodies of the present invention may be linked to each other and / or to one or more monomeric V H Or V L It may comprise homodimers or heterodimers (or other multimers) of any of the above-listed variable and constant domain configurations, with the domains non-covalently associated (eg, by disulfide bonds).

[0072] Like intact antibody molecules, antigen-binding fragments can be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding fragments of antibodies typically comprise at least two different variable domains, where each variable domain can specifically bind to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, can be adapted for use in the context of the antigen-binding fragments of antibodies of the present invention using routine techniques available in the art.

[0073] The antibodies of the present invention may function via complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). "Complement-dependent cytotoxicity" (CDC) refers to the lysis of antigen-expressing cells by the antibodies of the present invention in the presence of complement. "Antibody-dependent cell-mediated cytotoxicity" (ADCC) refers to a cell-mediated reaction in which nonspecific cytotoxic cells expressing Fc receptors (FcRs) (e.g., natural killer (NK) cells, neutrophils, and macrophages) recognize bound antibodies on target cells and thereby cause lysis of the target cells. CDC and ADCC can be measured using assays well known and available in the art. (See, e.g., U.S. Patent Nos. 5,500,362 and 5,821,337, and Clynes et al. (1998) Proc. Natl. Acad. Sci. (USA) 95:652-656.) The constant region of an antibody is important in the ability of an antibody to fix complement and mediate cell-dependent cytotoxicity. Thus, an antibody isotype can be selected based on whether the antibody is desirable for mediating cytotoxicity.

[0074] In certain embodiments of the present invention, the anti-CD3 antibodies (monospecific or bispecific) of the present invention are human antibodies. As used herein, the term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies of the present invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutation in vivo), e.g., in the CDRs, and particularly in CDR3. However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, e.g., a mouse, have been grafted onto human framework sequences.

[0075] The antibodies of the present invention may, in some embodiments, be recombinant human antibodies. As used herein, the term "recombinant human antibody" is intended to include all human antibodies that are produced, expressed, generated, or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) transgenic for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295), or antibodies produced, expressed, generated, or isolated by any other means, including splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis), thus modifying the V and C regions of the recombinant antibody. H and V L The amino acid sequence of the region is human germline V H and V L Sequence-derived and human germline Series V H and V L Although related in sequence, they may not naturally occur within the human antibody germline repertoire in vivo.

[0076] Human antibodies can exist in two forms related to hinge heterogeneity. In one form, the immunoglobulin molecule contains a stable four-chain construct of approximately 150-160 kDa, in which dimers are held together by interchain heavy chain disulfide bonds. In the second form, the dimers are not linked via interchain disulfide bonds, and a molecule of approximately 75-80 kDa is formed, composed of covalently coupled light and heavy chains (half antibodies). These forms have been very difficult to separate, even after affinity purification.

[0077] The frequency of occurrence of the second form in various intact IgG isotypes is due to, but not limited to, structural differences associated with antibody hinge region isotypes. A single amino acid substitution in the hinge region of a human IgG4 hinge is exemplified using a human IgG1 hinge. This can significantly reduce the occurrence of the second form to levels typically observed (Angal et al. al. (1993) Molecular Immunology 30:105). The present invention provides a hinge, C H 2 or C H Antibodies with one or more mutations in three regions are included, which may be desirable in manufacturing, for example, to improve yield of the desired antibody form.

[0078] The antibody of the present invention may be an isolated antibody. As used herein, an "isolated antibody" refers to an antibody that has been identified and separated and / or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which it naturally occurs or is naturally produced, is an "isolated antibody" for purposes of the present invention. An isolated antibody also includes an antibody in situ within a recombinant cell. An isolated antibody is an antibody that has been subjected to at least one purification or isolation step. According to certain embodiments, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0079] The present invention also includes one-arm antibodies that bind to CD3. As used herein, "one-arm antibody" refers to an antigen-binding molecule comprising a single antibody heavy chain and a single antibody light chain. The one-arm antibodies of the present invention may comprise any of the HCVR / LCVR or CDR amino acid sequences shown in Table 1 or Tables 18 / 19 herein.

[0080] The anti-CD3 antibodies disclosed herein may contain one or more amino acid substitutions, insertions, and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences from which the antibodies are derived. Such mutations can be readily identified by comparing the amino acid sequences disclosed herein to germline sequences available, for example, from public antibody sequence databases. The present invention includes antibodies and antigen-binding fragments thereof derived from any of the amino acid sequences disclosed herein, in which one or more amino acids in one or more framework and / or CDR regions are mutated to the corresponding residue in the germline sequence from which the antibody is derived, or to the corresponding residue in another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue (such sequence changes are collectively referred to herein as "germline mutations"). Starting with the heavy and light chain variable region sequences disclosed herein, one of skill in the art can readily produce numerous antibodies and antigen-binding fragments containing one or more individual germline mutations or combinations thereof. In certain embodiments, V H and / or V LAll framework and / or CDR residues within a domain are backmutated to residues found in the original germline sequence from which the antibody was derived. In other embodiments, only certain residues are backmutated to the original germline sequence, e.g., only mutated residues found within the first eight amino acids of FR1 or the last eight residues of FR4, or only mutated residues found in CDR1, CDR2, or CDR3. In other embodiments, one or more of the framework and / or CDR residues are mutated to the corresponding residue in a different germline sequence (i.e., a germline sequence that differs from the germline sequence from which the antibody was originally derived). Furthermore, antibodies of the invention can contain any combination of two or more germline mutations within the framework and / or CDR regions, e.g., where certain individual residues are mutated to the corresponding residue in a particular germline sequence, while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue in a different germline sequence. Once obtained, antibodies and antigen-binding fragments containing one or more germline mutations can be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonist or agonist biological properties (as the case may be), reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present invention.

[0081] The present invention also includes anti-CD3 antibodies comprising variants of any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein, having one or more conservative substitutions. For example, the present invention includes anti-CD3 antibodies having HCVR, LCVR, and / or CDR amino acid sequences that contain, for example, 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed in Table 1 herein.

[0082] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of an antibody molecule, known as the paratope. A single antigen can have more than one epitope. Thus, different antibodies may bind to different regions of an antigen and have different biological effects. Epitopes can be either conformational or linear. Conformational epitopes are formed by spatially adjacent amino acids from different segments of a linear polypeptide chain. Linear epitopes are formed by adjacent amino acid residues in a polypeptide chain. In certain circumstances, epitopes can include saccharide, phosphoryl, or sulfonyl moieties on the antigen.

[0083] The terms "substantial identity" or "substantially identical" when referring to a nucleic acid or fragment thereof indicates that when optimally aligned, with appropriate nucleotide insertions or deletions, with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 95%, and more preferably at least about 96%, 97%, 98%, or 99% of the nucleotide bases, as measured by any well-known algorithm for sequence identity, such as FASTA, BLAST, or Gap, as discussed below. A nucleic acid molecule having substantial identity to a reference nucleic acid molecule will, in certain cases, encode a polypeptide having the same or substantially similar amino acid sequence as the polypeptide encoded by the reference nucleic acid molecule.

[0084] The terms "substantial similarity" or "substantially similar," as applied to polypeptides, refer to two peptide sequences that share at least 95% sequence identity, and even more preferably at least 98% or 99% sequence identity, when optimally aligned, e.g., by the programs GAP or BESTFIT using default gap weights. Preferably, non-identical residue positions differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). Generally, conservative amino acid substitutions do not substantially alter the functional properties of a protein. When two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upward to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. See, e.g., Pearson (1994) Methods Mol. Biol. 24:307-331. Examples of groups of amino acids having side chains with similar chemical properties include: (1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic-hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartic acid and glutamic acid; and (7) sulfur-containing side chains: cysteine ​​and methionine. Preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative substitution is any change that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256:1443-1445. A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.

[0085] Sequence similarity (also called sequence identity) of polypeptides is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions, and other modifications, including conservative amino acid substitutions. For example, GCG software includes programs such as Gap and Bestfit, which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species, or between a wild-type protein and its mutein. See, for example, GCG version 6.1. Polypeptide sequences can also be compared using FASTA, a program in GCG version 6.1, using default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of best overlap between the query and search sequences (see Pearson (2000) supra). Another preferred algorithm for comparing the sequences of the present invention to a database containing a large number of sequences from different organisms is the computer program BLAST, particularly BLASTP or TBLASTN, using default parameters. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic Acids Res. 25:3389-402.

[0086] Bispecific antigen binding molecules The antibodies of the present invention may be monospecific, bispecific, or multispecific. Multispecific antibodies may be specific for different epitopes of a single target polypeptide or may contain antigen-binding domains specific for more than one target polypeptide. See, for example, Tutt et al., 1991, J. Immunol. 147:60-69; Kufer et al., 2004, Trends Biotechnol. 22:238-244. The anti-CD3 antibodies of the present invention may be linked to or coexpressed with another functional molecule, such as another peptide or protein. For example, an antibody or fragment thereof may be operatively linked (e.g., by chemical coupling, genetic fusion, noncovalent bonding, or otherwise) to one or more other molecular entities, such as another antibody or antibody fragment, to generate a bispecific or multispecific antibody with a second binding specificity.

[0087] The use of the phrase "anti-CD3 antibody" herein is intended to include both monospecific anti-CD3 antibodies as well as bispecific antibodies comprising a CD3-binding arm and a second arm that binds to a target antigen. Thus, the present invention includes bispecific antibodies in which one immunoglobulin arm binds to human CD3 and the other immunoglobulin arm is specific for a target antigen. The target antigen bound by the other arm of the CD3 bispecific antibody can be any antigen expressed on or near cells, tissues, organs, microorganisms, or viruses against which a targeted immune response is desired. The CD3-binding arm can comprise any of the HCVR / LCVR or CDR amino acid sequences shown in Table 1 or Table 18 / 19 herein. In certain embodiments, the CD3-binding arm binds to human CD3 and induces human T-cell proliferation.

[0088] In the context of a bispecific antibody of the present invention, in which one arm of the antibody binds to CD3 and the other arm binds to a target antigen, the target antigen can be a tumor-associated antigen. Non-limiting examples of specific tumor-associated antigens include, for example, AFP, ALK, BAGE protein, β-catenin, brc-abl, BRCA1, BORIS, CA9, carbonic anhydrase IX, caspase-8, CCR5, CD19, CD20, CD30, CD40, CDK4, CEA, CTLA4, cyclin-B1, CYP1B1, EGFR, EGFRvIII, ErbB2 / Her2, ErbB3, ErbB4, ETV6-AML, EpCAM, EphA2, Fra-1, FOLR1, GAGE ​​protein (e.g., GAGE-1, -2), GD2, and the like. , GD3, GloboH, glypican-3, GM3, gp100, Her2, HLA / B-raf, HLA / k-ras, HLA / MAGE-A3, hTERT, LMP2, MAGE proteins (e.g., MAGE-1, -2, -3, -4, -6, and -12), MART-1, mesothelin, ML-IAP, Muc1, Muc2, Muc3, Muc4, Muc5, Muc16 (CA-125), MUM1, NA17, NY-BR1, NY-BR6 2, NY-BR85, NY-ESO1, OX40, p15, p53, PAP, PAX3, PAX5, PCTA-1, PLAC1, PRLR, PRAME, PSMA (FOLH1), RAGE protein, Ras, RGS5, Rho, SART-1, SART-3, Steap-1, Steap-2, survivin, TAG-72, TGF-β, TMPRSS2, Tn, TRP-1, TRP-2, tyrosinase, and uroplakin-3.

[0089] In the context of a bispecific antibody of the invention in which one arm of the antibody binds to CD3 and the other arm binds to a target antigen, the target antigen can be an infectious disease-associated antigen. Non-limiting examples of infectious disease-associated antigens include, for example, antigens expressed on the surface of viral particles or preferentially expressed on cells infected with a virus, where the virus is selected from the group consisting of HIV, hepatitis (A, B, or C), herpesvirus (e.g., HSV-1, HSV-2, CMV, HAV-6, VZV, Epstein-Barr virus), adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackievirus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV, dengue virus, papillomavirus, molluscum contagiosum virus, poliovirus, rabies virus, JC virus, and arboviral encephalitis virus. Alternatively, the target antigen may be an antigen expressed on the surface of bacteria or preferentially expressed on cells infected with bacteria, wherein the bacteria is selected from the group consisting of chlamydia, rickettsia, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci, gonococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacillus, cholera, tetanus, botulism, anthrax, plague, leptospira, and bacteria of Lyme disease. In certain embodiments, the target antigen is an antigen expressed on the surface of a fungus or preferentially expressed on cells infected with a fungus, wherein the fungus is selected from the group consisting of Candida (e.g., Candida albicans, krusei, glabrata, tropicalis), Cryptococcus neoformans, Aspergillus (e.g., Fumigatus, Aspergillus niger), Mucorales (e.g., Mucor, Absidia, Rhizopus), Sporothrix schenkii, Blastomyces dermatitidis, South American blastocyst, Coccidioides immitis, and Histoplasma capsulatum.In certain embodiments, the target antigen is an antigen expressed on the surface of a parasite or preferentially expressed on cells infected with a parasite, wherein the parasite is selected from the group consisting of Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba spp., Giardia lambia, Cryptosporidium spp., Pneumocystis carinii, Plasmodium vivax, Babesia murine, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, Ancylostoma brasiliensis, Taenia crassiceps, and Brugia malayi. Non-limiting examples of specific pathogen-associated antigens include, for example, HIV gp120, HIV CD4, hepatitis B glucoprotein L, hepatitis B glucoprotein M, hepatitis B glucoprotein S, hepatitis C E1, hepatitis C E2, hepatocyte-specific protein, herpes simplex virus gB, cytomegalovirus gB, and HTLV envelope protein.

[0090] According to certain exemplary embodiments, the present invention comprises bispecific antigen-binding molecules that specifically bind to CD3 and CD20. Such molecules are referred to herein, e.g., as "anti-C The bispecific molecule may be referred to as "anti-CD3 / anti-CD20" or "anti-CD3xCD20" or "CD3xCD20" bispecific molecule, or other similar terminology.

[0091] As used herein, the term "CD20" refers to the human CD20 protein, unless specified as being from a non-human species (e.g., "mouse CD20," "monkey CD20," etc.). The human CD20 protein has the amino acid sequence set forth in SEQ ID NO: 1369.

[0092] As used herein, the phrase "antigen-binding molecule" refers to a protein, polypeptide, or molecular complex comprising or consisting of at least one complementarity-determining region (CDR), alone or in combination with one or more additional CDRs and / or framework regions (FR), that specifically binds to a particular antigen. In certain embodiments, the antigen-binding molecule is an antibody or antibody fragment, as those terms are defined elsewhere herein.

[0093] As used herein, the expression "bispecific antigen-binding molecule" refers to a protein, polypeptide, or molecular complex comprising at least a first antigen-binding domain and a second antigen-binding domain. Each antigen-binding domain in a bispecific antigen-binding molecule comprises at least one CDR that specifically binds to a particular antigen, either alone or in combination with one or more additional CDRs and / or FRs. In the context of the present invention, the first antigen-binding domain specifically binds to a first antigen (e.g., CD3), and the second antigen-binding domain specifically binds to a second, different antigen (e.g., CD20).

[0094] In certain exemplary embodiments of the present invention, the bispecific antigen-binding molecule is a bispecific antibody. Each antigen-binding domain of a bispecific antibody comprises a heavy chain variable domain (HCVR) and a light chain variable domain (LCVR). In the context of a bispecific antigen-binding molecule (e.g., a bispecific antibody) comprising a first and a second antigen-binding domain, the CDRs of the first antigen-binding domain may be designated with the prefix "A1", and the CDRs of the second antigen-binding domain are designated with the prefix "A2". Thus, the CDRs of the first antigen-binding domain are referred to herein as A1-HCDR1, A1-HCDR2, and A1-HCDR3; and the CDRs of the second antigen-binding domain are referred to herein as A2-HCDR1, A2-HCDR2, and A2-HCDR3.

[0095] The first antigen-binding domain and the second antigen-binding domain can be directly or indirectly connected to each other to form a bispecific antigen-binding molecule of the present invention. Alternatively, the first antigen-binding domain and the second antigen-binding domain can each be connected to a separate multimerization domain. Binding of one multimerization domain to another multimerization domain facilitates binding between the two antigen-binding domains, thereby forming a bispecific antigen-binding molecule. As used herein, a "multimerization domain" is any macromolecule, protein, polypeptide, peptide, or amino acid that has the ability to bind to a second multimerization domain of the same or similar structure or composition. For example, a multimerization domain can be connected to a second multimerization domain of the same or similar structure or composition. H 3 domains Non-limiting examples of multimerizing components include immunoglobulins (C H 2-C H The Fc portion of an IgG antibody may be an Fc domain of an IgG antibody having one or more Fc domains (comprising three domains), for example, the Fc domain of an IgG selected from the isotypes IgG1, IgG2, IgG3, and IgG4, as well as any allotype within each isotype group.

[0096] The bispecific antigen-binding molecules of the present invention typically comprise two multimerization domains, e.g., two Fc domains, each of which is part of a separate, distinct antibody heavy chain. The first and second multimerization domains may be of the same IgG isotype, e.g., IgG1 / IgG1, IgG2 / IgG2, IgG4 / IgG4, or the like. Alternatively, the first and second multimerization domains may be of the same IgG isotype, e.g., IgG1 / IgG2, IgG1 / IgG4, IgG2 / IgG4, or the like. It may be of a different IgG isotype, such as G4.

[0097] In certain embodiments, the multimerization domain is an Fc fragment or an amino acid sequence of 1 to about 200 amino acids in length containing at least one cysteine ​​residue. In other embodiments, the multimerization domain is a cysteine ​​residue or a short cysteine-containing peptide. Other multimerization domains include peptides or polypeptides comprising or consisting of a leucine zipper, a helix-loop motif, or a coiled-coil motif.

[0098] Any bispecific antibody format or formats can be used to generate the bispecific antigen-binding molecules of the invention. For example, an antibody or fragment thereof with a first antigen-binding specificity can be operably linked (e.g., by chemical coupling, genetic fusion, non-covalent bonding, or other methods) to one or more other molecular entities, such as another antibody or antigen fragment with a second antigen-binding specificity, to generate the bispecific antigen-binding molecule. Specific exemplary bispecific formats that can be used in the context of the present invention include, but are not limited to, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, quadroma, knobs-into-holes, common light chains (e.g., common light chains with knobs and holes), CrossMab, CrossFab, (SEED)body, leucine zipper, Duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab. 2 Bispecific formats (for a review of the aforementioned formats, see e.g. , Klein et al. 2012, mAbs 4:6, 1-11, and references cited therein).

[0099] In the context of the bispecific antigen-binding molecules of the present invention, the multimerization domain, e.g., the Fc domain, may contain one or more amino acid changes (e.g., insertions, deletions, or substitutions) compared to the wild-type, naturally occurring form of the Fc domain. For example, the present invention includes bispecific antigen-binding molecules containing one or more modifications in the Fc domain that result in a modified Fc domain with altered binding interactions (e.g., enhanced or decreased) between Fc and FcRn. In one embodiment, the bispecific antigen-binding molecule is H 2 or C H 3 region, where the modification is in an acidic environment (e.g., when the pH is about These modifications increase the affinity of the Fc domain for FcRn (in endosomes, ranging from about 5.5 to about 6.0). Non-limiting examples of such Fc modifications include modifications at positions 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T), and 256 (e.g., S / R / Q / E / D or T); or positions 428 and / or 433 (e.g., L / R / S / P / Q or K) and / or 434 (e.g., H / F or Y); or modifications at positions 250 and / or 428; or modifications at positions 307 or 308 (e.g., 308F, V308F), and 434. In one embodiment, the modifications include 428L (e.g., M428L) and 434S (e.g., N434S) modifications; 428L, 259I (e.g., V259I), and 308F (e.g., V308F) modifications; 433K (e.g., H433K) and 434 (e.g., 434Y) modifications; 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modifications; 250Q and 428L modifications (e.g., T250Q and M428L); and 307 and / or 308 modifications (e.g., 308F or 308P).

[0100] The present invention also provides a first C H 3 domain and second Ig C H and a bispecific antigen-binding molecule comprising three domains, wherein the first and second Ig CH The three domains must be at least 1 at least one amino acid difference, and wherein the at least one amino acid difference reduces binding of the bispecific antibody to Protein A compared to a bispecific antibody without the amino acid difference. In one embodiment, the first Ig C H The 3 domain binds to protein A, and the 4 domain binds to Second Ig C H The 3 domains are H95R (according to IMGT exon numbering; EU numbering) The second C contains a mutation that reduces or eliminates Protein A binding, such as the H435R mutation. H 3 further contains the Y96F (by IMGT; Y436F in EU) modification. It can be seen. Second C H Further modifications that may be found within 3 include: for IgG1 antibodies, D 16E, L18M, N44S, K52N, V57M, and V82I (according to IMGT; D356E, L358M, N384S, K392N, V397M, and V422I in EU); for IgG2 antibodies, N44S, K52N, and V82I (according to IMGT; N384S, K392N, and V422I in EU); and for IgG4 antibodies, Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (according to IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I in EU).

[0101] In certain embodiments, the Fc domain can be chimeric, combining Fc sequences from more than one immunoglobulin isotype. For example, the chimeric Fc domain can be human IgG1, human IgG2, or human IgG4 C. H C from two regions H Part or all of the 2 sequences, and C derived from human IgG1, human IgG2 or human IgG4 H 3. Part or all of the sequence The chimeric Fc domain may also contain a chimeric hinge region. For example, the chimeric hinge may comprise an "upper hinge" sequence derived from a human IgG1, human IgG2, or human IgG4 hinge region in combination with a "lower hinge" sequence derived from a human IgG1, human IgG2, or human IgG4 hinge region. A specific example of a chimeric Fc domain that may be included in any of the antigen-binding molecules provided herein is, from the N-terminus to the C-terminus: [IgG4 C H 1]-[I Another example of a chimeric Fc domain that may be included in any of the antigen-binding molecules described herein includes, from the N-terminus to the C-terminus: [IgG1 C upper hinge]-[IgG2 C lower hinge]-[IgG4 C H2]-[IgG4 C H3]. H 1]-[IgG1 upper hinge] -[IgG2 lower hinge]-[IgG4 CH2]-[IgG1 CH3]. These and other examples of chimeric Fc domains that may be included in any of the antigen-binding molecules of the invention are described in U.S. Provisional Application No. 61 / 759,578 (filed February 1, 2013). Chimeric Fc domains with these general structural arrangements, and variants thereof, may have altered Fc receptor binding, which in turn affects Fc effector function.

[0102] Sequence variants The antibodies and bispecific antigen-binding molecules of the present invention may contain one or more amino acid substitutions, insertions, and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences from which the individual antigen-binding domains are derived. Such mutations can be readily identified by comparing the amino acid sequences disclosed herein with germline sequences available, for example, from public antibody sequence databases. The antigen-binding molecules of the present invention may comprise an antigen-binding domain derived from any of the exemplary amino acid sequences disclosed herein, wherein one or more amino acids in one or more framework and / or CDR regions are mutated to the corresponding residue in the germline sequence from which the antibody is derived, or to the corresponding residue in another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue (such sequence changes are collectively referred to herein as "germline mutations"). Starting from the heavy and light chain variable region sequences disclosed herein, one skilled in the art can easily produce numerous antibodies and antigen-binding fragments containing one or more individual germline mutations or combinations thereof. In certain embodiments, V H and / or V L All of the framework and / or CDR residues within a domain are antigen-binding domains. In other embodiments, only certain residues are mutated back to those found in the original germline sequence from which the amino acid sequence was originally derived, e.g., only mutated residues found within the first 8 amino acids of FR1 or the last 8 amino acids of FR4, or only mutated residues found within CDR1, CDR2, or CDR3. In other embodiments, one or more framework and / or CDR residues are mutated to the corresponding residue in a different germline sequence (i.e., a germline sequence different from the germline sequence from which the antigen-binding domain was originally derived). Furthermore, an antigen-binding domain can contain any combination of two or more germline mutations within the framework and / or CDR regions, for example, where certain individual residues are mutated to the corresponding residue in a particular germline sequence, while certain other residues that differ from the original germline sequence are maintained, or where the original germline sequence is maintained or mutated to the corresponding residue in a different germline sequence. Once obtained, an antigen-binding domain containing one or more germline mutations can be readily tested for one or more desirable properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonist or agonist biological properties (as the case may be), reduced immunogenicity, etc. Bispecific antigen-binding molecules comprising one or more antigen-binding domains obtained in this general manner are encompassed within the present invention.

[0103] The present invention also includes antigen-binding molecules in which one or both antigen-binding domains comprise variants of any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein with one or more conservative substitutions. For example, the present invention includes antigen-binding molecules comprising antigen-binding domains having HCVR, LCVR, and / or CDR amino acid sequences with, for example, 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). Generally, conservative amino acid substitutions do not substantially alter the functional properties of a protein. Examples of groups of amino acids having side chains with similar chemical properties include: (1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic-hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartic acid and glutamic acid; and (7) sulfur-containing side chains: cysteine ​​and methionine. Preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative substitution is any change that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256:1443-1445. A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.

[0104] The present invention also includes antigen-binding molecules comprising an antigen-binding domain having an HCVR, LCVR, and / or CDR amino acid sequence substantially identical to any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein. The terms "substantial identity" or "substantially identical," when referring to amino acid sequences, mean two amino acid sequences that share at least 95% sequence identity, and even more preferably at least 98% or 99% sequence identity, when optimally aligned, for example, by the programs GAP or BESTFIT using default gap weights. Preferably, residue positions that are not identical differ by conservative amino acid substitutions. When two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upward to correct for the conservative nature of the substitutions. Means for making this adjustment are well known to those of skill in the art. See, e.g., Pearson (1994) Methods Mol. Biol. 24:307-331.

[0105] Sequence similarity (also called sequence identity) for polypeptides is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions, and other modifications, including conservative amino acid substitutions. For example, GCG software includes programs such as Gap and Bestfit, which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species, or between a wild-type protein and its mutein. See, for example, GCG version 6.1. Polypeptide sequences can also be compared using FASTA, a program in GCG version 6.1, using default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of best overlap between the query and search sequences (see Pearson (2000) supra). Another preferred algorithm for comparing the sequences of the present invention to a database containing a large number of sequences from different organisms is the computer program BLAST, particularly BLASTP or TBLASTN, using default parameters. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic Acids Res. 25:3389-402.

[0106] pH dependent binding The present invention includes anti-CD3 antibodies and anti-CD3 / anti-CD20 bispecific antigen-binding molecules with pH-dependent binding characteristics. For example, anti-CD3 antibodies of the present invention may exhibit decreased binding to CD3 at acidic pH compared to neutral pH. Alternatively, anti-CD3 antibodies of the present invention may exhibit enhanced binding to CD3 at acidic pH compared to neutral pH. The term "acidic pH" includes pH values ​​below about 6.2, e.g., about 6.0, 5.95, 5.9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0, or lower. As used herein, the term "neutral pH" refers to a pH of about 7.0 to about 7.4. The expression "neutral pH" includes pH values ​​of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.

[0107] In some cases, "decreased binding at acidic pH compared to neutral pH" refers to the K of binding of an antibody to its antigen at neutral pH. D value, the antibody to that antigen at acidic pH Bond K D It is expressed as a ratio of the values ​​(or vice versa). For example, an antibody or its antigen-binding fragment The antibody or antigen-binding fragment thereof has an acidic / neutral K of about 3.0 or greater. D When a ratio is presented, it can be considered for the purposes of the present invention to indicate "decreased binding to CD3 at acidic pH compared to neutral pH." In certain exemplary embodiments, the acidic / neutral K D The ratios are approximately 3.0, 3.5, and 4. It can be 0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 100.0 or more.

[0108] Antibodies with pH-dependent binding characteristics can be obtained, for example, by screening antibody populations for decreased (or enhanced) binding to a particular antigen at acidic pH compared to neutral pH. Furthermore, antibodies with pH-dependent characteristics can be obtained by modifying the antigen-binding domain at the amino acid level. For example, by substituting one or more amino acids in the antigen-binding domain (e.g., within the CDRs) with histidine residues, an antibody with decreased antigen binding at acidic pH compared to neutral pH can be obtained.

[0109] Antibodies containing Fc variants Certain embodiments of the present invention provide anti-CD3 antibodies and anti-CD3 / anti-CD20 bispecific antigen-binding molecules comprising an Fc domain containing one or more mutations that enhance or decrease binding of the antibody to the FcRn receptor, e.g., at acidic pH compared to neutral pH. For example, the present invention provides an Fc domain comprising one or more mutations that enhance or decrease binding of the antibody to the FcRn receptor at acidic pH compared to neutral pH. H 2 or C HThese antibodies include those containing mutations in the three regions, which increase the affinity of the Fc domain for FcRn in acidic environments (e.g., in endosomes, where the pH ranges from about 5.5 to about 6.0). Such mutations can result in an increased serum half-life of the antibody when administered to an animal. Non-limiting examples of such Fc modifications include, for example, modifications at positions 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T), and 256 (e.g., S / R / Q / E / D or T); or modifications at positions 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or 434 (e.g., H / F or Y); or modifications at positions 250 and / or 428; or modifications at positions 307 or 308 (e.g., 308F, V308F), and 434. In one embodiment, the modifications include 428L (e.g., M428L) and 434S (e.g., N434S) modifications; 428L, 259I (e.g., V259I), and 308F (e.g., V308F) modifications; 433K (e.g., H433K) and 434 (e.g., 434Y) modifications; 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modifications; 250Q and 428L modifications (e.g., T250Q and M428L); and 307 and / or 308 modifications (e.g., 308F or 308P).

[0110] For example, the present invention includes anti-CD3 antibodies and anti-CD3 / anti-CD20 bispecific antigen-binding molecules comprising an Fc domain containing one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T and 256E (e.g., M252Y, S254T and T256E); 428L and 434S (e.g., M428L and N434S); and 433K and 434F (e.g., H433K and N434F). All possible combinations of the foregoing Fc domain mutations, and other mutations in antibody variable domains disclosed herein, are considered within the scope of the present invention.

[0111] Biological characteristics of antibodies and bispecific antigen-binding molecules The present invention includes antibodies and antigen-binding fragments thereof that bind to human CD3 and induce T cell proliferation. For example, the present invention provides antibodies and antigen-binding fragments thereof that have an EC of less than about 0.33 pM as measured by an in vitro T cell proliferation assay, e.g., using the assay format defined in Example 4 herein (e.g., assessing proliferation of Jurkat cells or human PBMCs in the presence of an anti-CD3 antibody), or a substantially similar assay. 50 In certain embodiments, the antibodies or antigen-binding fragments of the invention have an EC value of less than about 0.32 pM, less than about 0.31 pM, less than about 0.30 pM, less than about 0.28 pM, less than about 0.26 pM, less than about 0.24 pM, less than about 0.22 pM, or less than about 0.20 pM, as measured by an in vitro T cell proliferation assay, e.g., using the assay format set forth in Example 4 herein, or a substantially similar assay. 50 Induce human T cell proliferation (e.g., Jurkat cell proliferation and / or PBMC proliferation) at these values.

[0112] The present invention also includes antibodies and antigen-binding fragments thereof that bind to human CD3 and induce T cell-mediated killing of tumor cells. For example, the present invention provides antibodies and antigen-binding fragments thereof that have an ECA of less than about 2.3 pM as measured in an in vitro T cell-mediated tumor cell killing assay, e.g., using the assay format set forth herein in Example 6 (e.g., assessing the extent of U937 tumor cell killing by human PBMCs in the presence of an anti-CD3 antibody), or a substantially similar assay. 50 In certain embodiments, the antibodies or antigen-binding fragments of the invention are used in assay formats such as those set forth in Example 6 herein, including anti-CD3 antibodies that induce T cell-mediated killing of tumor cells. or an EC50 of less than about 2.3 pM, less than about 2.2 pM, less than about 2.1 pM, less than about 2.0 pM, less than about 1.8 pM, less than about 1.6 pM, less than about 1.4 pM, less than about 1.2 pM, less than about 1.0 pM, less than about 0.8 pM, less than about 0.6 pM, or less than about 0.5 pM as measured by an in vitro T-cell mediated tumor cell killing assay using a substantially similar assay. 50At these values, it induces T cell-mediated tumor cell killing (e.g., PBMC-mediated killing of U937 cells).

[0113] The present invention includes antibodies and antigen-binding fragments thereof that bind to human CD3 with high affinity. The present invention also includes antibodies and antigen-binding fragments thereof that bind to human CD3 with moderate or low affinity, depending on the therapeutic situation and the specific target characteristics desired. For example, in the context of a bispecific antigen-binding molecule in which one arm binds to CD3 and another arm binds to a target antigen (e.g., CD20), it may be desirable for the target antigen-binding arm to bind to the target antigen with high affinity, while the anti-CD3 arm binds to CD3 with only moderate or low affinity. In this way, preferential targeting of the antigen-binding molecule to cells expressing the target antigen can be achieved while avoiding total / non-target CD3 binding and the resulting adverse side effects associated with it.

[0114] According to certain embodiments, the present invention provides a method for treating rhodopsin-related ... D Dehi In certain embodiments, antibodies or antigen-binding fragments of the invention have a K of less than about 5 nM, less than about 2 nM, less than about 1 nM, less than about 800 pM, less than about 600 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 180 pM, less than about 160 pM, less than about 140 pM, less than about 120 pM, less than about 100 pM, less than about 80 pM, less than about 60 pM, less than about 40 pM, less than about 20 pM, or less than about 10 pM, as measured by surface plasmon resonance, e.g., using an assay format (e.g., mAb-capture or antigen capture format) set forth in Example 3 herein, or a substantially similar assay. D binds to CD3.

[0115] The present invention also provides compounds having a dissociation half-life (t) of greater than about 10 minutes, as measured by surface plasmon resonance at 25° C. or 37° C., for example, using the assay format defined in Example 3 herein, or a substantially similar assay. 1 / 2). In certain embodiments, the antibodies or antigen-binding fragments of the invention have a t of greater than about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than about 50 minutes, greater than about 60 minutes, greater than about 70 minutes, greater than about 80 minutes, greater than about 90 minutes, greater than about 100 minutes, greater than about 200 minutes, greater than about 300 minutes, greater than about 400 minutes, greater than about 500 minutes, greater than about 600 minutes, greater than about 700 minutes, greater than about 800 minutes, greater than about 900 minutes, greater than about 1000 minutes, or greater than about 1200 minutes, as measured by surface plasmon resonance at 25°C or 37°C, e.g., using an assay format (e.g., mAb capture or antigen capture format) set forth in Example 3 herein, or a substantially similar assay. 1 / 2 binds to CD3.

[0116] The present invention includes bispecific antigen-binding molecules (e.g., bispecific antibodies) that can simultaneously bind to human CD3 and human CD20. According to certain embodiments, the bispecific antigen-binding molecules of the present invention specifically interact with cells expressing CD3 and / or CD20. The extent to which a bispecific antigen-binding molecule binds to cells expressing CD3 and / or CD20 can be assessed by fluorescence-activated cell sorting (FACS), as described in Example 8 herein. For example, the present invention relates to the binding of a bispecific antigen-binding molecule to cells expressing CD3 and / or CD20 using a human T cell line (e.g., Jurkat) that expresses CD3 but not CD20, a human B cell line (e.g., Raji) that expresses CD20 but not CD3, and / or primate T cells (e.g., cynomolgus monkey peripheral blood mononuclear cells). The present invention provides a bispecific antigen-binding molecule that specifically binds to approximately 9.0 x 10 PBMCs, as determined using the FACS assay described in Example 8 or a substantially similar assay. -6 ~about 2.0x10 -9 or lower EC 50and a bispecific antigen-binding molecule that binds to any of the aforementioned cells and cell lines at a value of 0.1.

[0117] The present invention also provides antibodies with an EC50 activity between 1.0 pM and 1000 nM on human T cells (e.g., Jurkat) expressing CD3. 50 In certain embodiments, the anti-CD3 / anti-CD20 bispecific antigen-binding molecules bind to CD3-expressing human T cells with an EC50 value between 1 nM and 60 nM. For example, the present invention provides anti-CD3 / anti-CD20 bispecific antigen-binding molecules that bind to CD3-expressing human T cells (e.g., Jurkat) with an EC50 value of about 1 pM, about 10 pM, about 100 pM, about 500 pM, about 1 nM, about 2 nM, about 5 nM, about 10 nM, about 20 nM, about 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM, about 200 nM, about 300 nM, about 500 nM, about 800 nM, about 1000 nM or more. 50 The present invention also includes an anti-CD3 / anti-CD20 bispecific antigen-binding molecule that binds at a single antibody.

[0118] The present invention also includes anti-CD3 / anti-CD20 bispecific antigen-binding molecules that exhibit one or more characteristics selected from the group consisting of: (a) inducing PBMC proliferation in vitro (see, e.g., Example 9 herein); (b) activating T cells and inducing IFN-gamma release and CD25 upregulation in human whole blood (see, e.g., Example 10 herein); (c) inducing T cell-mediated cytotoxicity against anti-CD20-resistant cell lines (see, e.g., Example 11 herein); (d) inducing cytotoxicity against human B cells (e.g., Raji; see, e.g., Example 13 herein); (e) depleting B cells (e.g., CD19+ B cells) in mice reconstituted with human immune cells (see, e.g., Example 14 herein); and (f) reducing B cell tumor volume (e.g., Raji tumor volume) in mouse xenografts (see, e.g., Example 15).

[0119] The present invention includes anti-CD3 / anti-CD20 bispecific antigen-binding molecules that are capable of depleting B cells in a subject (see, e.g., Example 16). For example, according to certain embodiments, anti-CD3 / anti-CD20 bispecific antigen-binding molecules are provided, wherein a single administration of the bispecific antigen-binding molecule to a subject (e.g., at a dose of about 0.1 mg / kg, about 0.08 mg / kg, about 0.06 mg / kg, about 0.04 mg / kg, about 0.04 mg / kg, about 0.02 mg / kg, about 0.01 mg / kg or less) causes a reduction in the number of B cells in the subject below detectable levels (e.g., in a blood sample taken from the subject). In certain embodiments, a single administration of an anti-CD3 / anti-CD20 bispecific antigen-binding molecule at a dose of about 0.1 mg / kg causes a decrease in B cell numbers in a subject below detectable levels by about 7, about 6, about 5, about 4, about 3, about 2, or about 1 day after administration of the bispecific antigen-binding molecule to the subject. According to certain embodiments, a single administration of an anti-CD3 / anti-CD20 bispecific antigen-binding molecule of the invention at a dose of about 0.01 mg / kg causes B cell numbers to remain below detectable levels for at least about 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or more days after administration. As used herein, the phrase "below detectable levels" means that B cells cannot be detected, either directly or indirectly, in a blood sample taken from a subject using a standard B cell detection assay, e.g., a FACS assay for B cell markers, as shown in Example 16 herein.

[0120] In a related embodiment, an anti-CD3 / anti-CD20 bispecific antigen-binding molecule is provided, wherein about 1 day after administration of a single dose of about 0.01 mg / kg of the antigen-binding molecule to a subject In certain other embodiments, the number of B cells per microliter of blood drawn from the subject about 28 days after administration is less than 25% of the number of B cells per microliter of blood drawn from the subject prior to administration. In certain other embodiments, anti-CD3 / anti-CD20 bispecific antigen-binding molecules are provided, wherein about 1 day to about 56 days after administration of a single dose of about 0.01 mg / kg of the antigen-binding molecule to the subject, the number of B cells per microliter of blood drawn from the subject is less than 50% of the number of B cells per microliter of blood drawn from the subject prior to administration.

[0121] The present invention also provides anti-CD3 / anti-CD20 bispecific antigen-binding molecules that, when administered to a subject, cause only a temporary decrease in T cells. For example, anti-CD3 / anti-CD20 bispecific antigen-binding molecules are provided that, when administered to a subject at a dose of about 0.01 mg / kg, reduce T cell counts one day after administration, but the number of T cells per microliter of blood recovers at a later time point (e.g., by about 2, 7, 14, 28, 42, 56, or more days after administration). For example, the present invention provides anti-CD3 / anti-CD20 bispecific antigen-binding molecules, wherein about 14 to about 56 days after administration of the antigen-binding molecule to a subject, the number of T cells per microliter of blood collected from the subject is equal to or greater than the number of T cells per microliter of blood collected from the subject before administration of the bispecific antigen-binding molecule.

[0122] Epitope mapping and related techniques The epitope on CD3 to which the antigen-binding molecule of the present invention binds may consist of a single contiguous sequence of three or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) amino acids of the CD3 protein. Alternatively, the epitope may consist of multiple discontinuous amino acids (or amino acid sequences) of CD3. The antibodies of the present invention may interact with amino acids contained within a single CD3 chain (e.g., CD3-epsilon, CD3-delta, or CD3-gamma) or may interact with amino acids on two or more different CD3 chains. As used herein, the term "epitope" refers to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of an antibody molecule, known as the paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different regions of an antigen and have different biological effects. Epitopes can be either conformational or linear. Conformational epitopes are formed by spatially adjacent amino acids from different segments of a linear polypeptide chain. Linear epitopes are formed by adjacent amino acid residues in a polypeptide chain. In certain circumstances, epitopes may include saccharide, phosphoryl, or sulfonyl moieties on an antigen.

[0123] Various techniques known to those skilled in the art can be used to determine whether an antigen-binding domain of an antibody "interacts with one or more amino acids" of a polypeptide or protein. Exemplary techniques include, for example, AntibodiesThese include routine cross-blocking assays such as those described by Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harbor, NY), alanine scanning mutation analysis, peptide blot analysis (Reineke, 2004, Methods Mol Biol 248:443-463), and peptide truncation analysis. Additionally, methods such as epitope excision, epitope extraction, and chemical modification of antigens can be used (Tomer, 2000, Protein Science 9:487-496). Another method that can be used to identify amino acids in a polypeptide with which an antibody's antigen-binding domain interacts is hydrogen / deuterium exchange, detected by mass spectrometry. Broadly speaking, the hydrogen / deuterium exchange method involves deuterium labeling of the protein of interest, followed by binding of an antibody to the deuterium-labeled protein. The protein / antibody complex is then transferred to water to isolate residues protected by the antibody (these are deuterium-labeled). The antibody is then subjected to hydrogen-deuterium exchange at all residues except for the cleaved nucleotides (which remain unlabeled). After dissociation of the antibody, the target protein is subjected to protease cleavage and mass spectrometry, revealing deuterium-labeled residues corresponding to the specific amino acids with which the antibody interacts. See, e.g., Ehring (1999) Analytical Biochemistry 267(2):252-259; Engen and Smith (2001) Anal. Chem. 73:256A-265A. X-ray crystallography of antigen / antibody complexes can also be used for epitope mapping purposes.

[0124] The present invention further includes anti-CD3 antibodies that bind to the same epitope as any of the specific exemplary antibodies described herein (e.g., antibodies comprising any of the amino acid sequences set forth in Table 1 herein). Similarly, the present invention also includes anti-CD3 antibodies that compete for binding to CD3 with any of the specific exemplary antibodies described herein (e.g., antibodies comprising any of the amino acid sequences set forth in Table 1 herein).

[0125] The present invention also includes bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3 and a second antigen-binding domain that specifically binds human CD20, where the first antigen-binding domain binds to the same epitope on CD3 as any of the specific exemplary CD3-specific antigen-binding domains described herein, and / or the second antigen-binding domain binds to the same epitope on CD20 as any of the specific exemplary CD20-specific antigen-binding domains described herein.

[0126] Similarly, the present invention also includes bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3 and a second antigen-binding domain that specifically binds human CD20, where the first antigen-binding domain competes for binding to CD3 with any of the specific exemplary CD3-specific antigen-binding domains described herein and / or the second antigen-binding domain competes for binding to CD20 with any of the specific exemplary CD20-specific antigen-binding domains described herein.

[0127] Whether a particular antigen-binding molecule (e.g., an antibody) or its antigen-binding domain binds to the same epitope as a reference antigen-binding molecule of the invention, or competes for binding with it, can be easily determined using methods routine in the art. For example, to determine whether a test antibody binds to the same epitope on CD3 (or CD20) as a reference bispecific antigen-binding molecule of the invention, the reference bispecific molecule is first bound to the CD3 protein (or CD20 protein). The ability of the test antibody to bind to the CD3 (or CD20) molecule is then evaluated. If the test antibody is able to bind to CD3 (or CD20) after saturation binding with the reference bispecific antigen-binding molecule, it can be concluded that the test antibody binds to a different epitope on CD3 (or CD20) than the reference bispecific antigen-binding molecule. On the other hand, if the test antibody is unable to bind to CD3 (or CD20) after saturation binding with the reference bispecific antigen-binding molecule, the test antibody may bind to the same epitope on CD3 (or CD20) as the epitope bound by the reference bispecific antigen-binding molecule of the invention. Further routine experiments (e.g., peptide mutations and binding analysis) can then be performed to confirm whether the observed lack of binding of the test antibody is indeed due to binding to the same epitope as the reference bispecific antigen-binding molecule, or whether steric blocking (or another phenomenon) is responsible for the observed lack of binding. This type of experiment can be performed using ELISA, RIA, Biacore, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the art. According to certain embodiments of the invention, for example, a 1-fold, 5-fold, 10-fold, 20-fold, or 100-fold excess of one antigen-binding protein inhibits binding of the other by at least 50%, but preferably 75%, 90%, or even 99%, as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 1990:50:1495-1502). Two antigen-binding proteins bind to the same (or overlapping) epitope if: (a) the two antigen-binding proteins have the same or similar epitope; (b) the two antigen-binding proteins have the same or similar epitope if: (a) the two antigen-binding proteins have the same or similar epitope; (b) the two antigen-binding proteins have the same or similar epitope if: (a) the two antigen-binding proteins have the same or similar epitope; (b) the two antigen-binding proteins have the same or similar epitope if: (a) the two antigen-binding proteins have the same or similar epitope; (c) the two antigen-binding proteins have the same or similar epitope; (d) the two antigen-binding proteins have the same or similar epitope if: (a) the two antigen-binding proteins have the same or similar epitope; (b) the two antigen-binding proteins have the same or similar epitope; (c) the two antigen-binding proteins have the same or similar epitope; (d) the two antigen-binding proteins have the same or similar epitope; (e) the two antigen-binding proteins have the same or similar epitope; (e) the two antigen-binding proteins have the same or similar epitope; (e) the two antigen-binding proteins have the same or similar epitope; (e) the two antigen-binding proteins have the same or similar epitope; (f) the two antigen-binding proteins have the same or similar epitope; (f) the two antigen-binding proteins have the same or similar epitope; (g ...

[0128] To determine whether an antibody or its antigen-binding domain competes for binding with a reference antigen-binding molecule, the above-described binding methodology was performed in two ways: in the first direction, the reference antigen-binding molecule was allowed to bind to CD3 protein (or CD20 protein) under saturating conditions, followed by assessing the binding of the test antibody to the CD3 (or CD20) molecule. In the second direction, the test antibody was allowed to bind to CD3 (or CD20) molecules under saturating conditions, followed by assessing the binding of the reference antigen-binding molecule to CD3 (or CD20) molecules. If only the first (saturating) antigen-binding molecule can bind to CD3 (or CD20) molecules in both directions, it is concluded that the test antibody and the reference antigen-binding molecule compete for binding to CD3 (or CD20). Those skilled in the art will appreciate that an antibody that competes for binding with a reference antigen-binding molecule may not necessarily bind to the same epitope as the reference antibody, but may sterically block the binding of the reference antibody by binding to an overlapping or adjacent epitope.

[0129] Preparation of antigen-binding domains and construction of bispecific molecules Antigen-binding domains specific for a particular antigen can be produced by any antibody generation technique known in the art. Once obtained, two different antigen-binding domains specific for two different antigens (e.g., CD3 and CD20) can be appropriately positioned relative to each other to produce the bispecific antigen-binding molecules of the invention using conventional methods. (A discussion of exemplary bispecific antibody formats that can be used to construct the bispecific antigen-binding molecules of the invention is provided elsewhere herein.) In certain embodiments, one or more of the individual components (e.g., heavy and light chains) of the multispecific antigen-binding molecules of the invention are derived from chimeric, humanized, or fully human antibodies. Methods for producing such antibodies are well known in the art. For example, one or more of the heavy and / or light chains of the bispecific antigen-binding molecules of the invention can be derived from VELOCIMMUNE antibodies. TM It can be manufactured using the technology TM Using this technique (or any other method for generating human antibodies), high-affinity antibodies against a particular antigen (e.g., CD3 or CD20) with human variable regions and mouse constant regions are first isolated. The antibodies are characterized and selected for desired characteristics, including affinity, selectivity, epitope, etc. The mouse constant regions are replaced with the desired human constant regions to generate fully human heavy and / or light chains that can be incorporated into the bispecific antigen-binding molecules of the invention.

[0130] Genetically engineered animals can be used to create human bispecific antigen-binding molecules. For example, genetically modified mice can be used that are unable to rearrange and express endogenous mouse immunoglobulin light chain variable sequences, where the mice express only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to mouse kappa constant genes at the endogenous mouse kappa locus. Such genetically modified mice can be used to produce fully human bispecific antigen-binding molecules containing two different heavy chains associated with the same light chain, which contain variable domains derived from one of two different human light chain variable region gene segments. (For a detailed discussion of such engineered mice and their use to produce bispecific antigen-binding molecules, see, e.g., US2011 / 0195454.)

[0131] bioequivalence The present invention encompasses antigen-binding molecules that have amino acid sequences that differ from those of the exemplary molecules disclosed herein, but that retain the ability to bind to CD3 and / or CD20. Such variant molecules may contain one or more amino acid additions, deletions, or substitutions when compared to the parent sequence, but exhibit essentially equivalent biological activity to that of the described bispecific antigen-binding molecules.

[0132] The present invention includes antigen-binding molecules that are bioequivalent to any of the exemplary antigen-binding molecules presented herein. Two antigen-binding proteins, or antibodies, are considered bioequivalent if, for example, they are pharmaceutical equivalents or pharmaceutical substitutes whose rate and extent of absorption do not show significant differences when administered in either single or multiple doses at the same molar dose under similar experimental conditions. Some antigen-binding proteins are considered equivalents or pharmaceutical substitutes if they are equivalent in their extent of absorption but not in their rate of absorption; such differences in absorption rate are intentional and indicated on the label, are not essential, for example, to achieving effective body drug concentrations with chronic use, and are not medically significant with respect to the particular drug being studied, and may still be considered bioequivalent.

[0133] In one embodiment, two antigen binding proteins are bioequivalent if there are no clinically meaningful differences in their safety, purity, and potency.

[0134] In one embodiment, two antigen binding proteins are bioequivalent if a patient can be switched one or more times between the reference product and the biological product without an expected increase in the risk of adverse effects, including clinically significant changes in immunogenicity, or reduced efficacy, compared to continued treatment without switching.

[0135] In one embodiment, two antigen binding proteins are bioequivalent if they both act by a common mechanism(s) of action under the condition(s) of use, to the extent such mechanism(s) are known.

[0136] Bioequivalence may be demonstrated by in vivo and in vitro methods. Measures of bioequivalence include, for example, (a) in vivo studies in humans or other mammals in which the concentration of an antibody or its metabolites is measured as a function of time in blood, plasma, serum, or other biological fluids; (b) in vitro studies that correlate with and are reasonably predictive of human in vivo bioavailability data; (c) in vivo studies in humans or other mammals in which the relevant acute pharmacological effects of the antibody (or its target) are measured as a function of time; and (d) in well-controlled clinical trials that establish the safety, efficacy, or bioavailability or bioequivalence of the antigen-binding protein.

[0137] Biologically equivalent variants of the exemplary bispecific antigen-binding molecules shown herein can be constructed, for example, by making various substitutions of residues or sequences, or by removing terminal or internal residues or sequences that are not required for biological activity. For example, cysteine ​​residues are not essential for biological activity and can be removed or replaced with other amino acids to prevent the formation of unnecessary or incorrect intramolecular disulfide bridges during renaturation. In other situations, biologically equivalent antigen-binding proteins can include variants of the exemplary bispecific antigen-binding molecules shown herein that contain amino acid changes that alter the glycosylation characteristics of the molecule, for example, mutations that eliminate or remove glycosylation.

[0138] Species selectivity and species cross-reactivity According to certain embodiments of the present invention, antigen-binding molecules that bind to human CD3 but not to CD3 from other species are provided. Antigen-binding molecules that bind to human CD20 but not to CD20 from other species are also provided. The present invention also provides antigen-binding molecules that bind to human CD3 and CD3 from one or more non-human species; and / or human CD20 and antigen-binding molecules that bind to CD20 from one or more non-human species.

[0139] According to certain exemplary embodiments of the present invention, there are provided antigen-binding molecules that bind to human CD3 and / or human CD20, and optionally may or may not bind to one or more of mouse, rat, guinea pig, hamster, gerbil, pig, cat, dog, rabbit, goat, sheep, cow, horse, camel, cynomolgus monkey, marmoset, rhesus monkey, or chimpanzee CD3 and / or CD20. For example, in certain exemplary embodiments of the present invention, there are provided bispecific antigen-binding molecules comprising a first antigen-binding domain that binds to human CD3 and cynomolgus monkey CD3, and a second antigen-binding domain that specifically binds to human CD20.

[0140] immune complex The present invention encompasses antigen-binding molecules ("immunoconjugates") conjugated to a therapeutic moiety, such as a cytotoxin, a chemotherapeutic agent, an immunosuppressant, or a radioisotope. Cytotoxic agents include agents that are detrimental to cells. Examples of cytotoxic and chemotherapeutic agents suitable for forming immunoconjugates are known in the art (see, e.g., WO05 / 103081).

[0141] Therapeutic Formulations and Administration The present invention provides pharmaceutical compositions comprising the antigen-binding molecules of the present invention. The pharmaceutical compositions of the present invention are formulated with suitable carriers, additives, and other agents that provide improved transport, delivery, tolerance, etc. Many suitable formulations can be found in formularies known to all pharmacists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic)-containing vesicles (e.g., LIPOFECTIN TMExcipients for parenteral formulations include PEG-400 (Patent No. 10020001, Life Technologies, Carlsbad, CA), DNA conjugates, anhydrous absorbent pastes, oil-in-water and water-in-oil emulsions, carbowax emulsions (polyethylene glycol of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al., "Compendium of excipients for parenteral formulations," PDA (1998) J Pharm Sci Technol 52:238-311.

[0142] The dose of an antigen-binding molecule administered to a patient may vary depending on the patient's age and size, target disease, condition, route of administration, etc. Preferred doses are typically calculated according to body weight or body surface area. When a bispecific antigen-binding molecule of the present invention is used for therapeutic purposes in an adult patient, it may be advantageous to administer the bispecific antigen-binding molecule of the present invention intravenously at a single dose of typically about 0.01 to about 20 mg / kg body weight, more preferably about 0.02 to about 7, about 0.03 to about 5, or about 0.05 to about 3 mg / kg body weight. The frequency and duration of treatment may be adjusted depending on the severity of the condition. Effective dosages and schedules for administering bispecific antigen-binding molecules may be determined empirically; for example, the patient's progress may be monitored by periodic evaluation, and the dosage may be adjusted accordingly. Furthermore, interspecies scaling of dosages may be performed using methods well known in the art (e.g., Mordenti et al., 1991, Pharmaceut. Res. 8:1351).

[0143] Various delivery systems are known and can be used to administer the pharmaceutical compositions of the present invention, for example, liposome encapsulation, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis (see, e.g., Wu et al., J. Immunol. 1999, 103:111-114). et al., 1987, J.Biol.Chem.262:4429-4432. (See references). Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and may be administered together with other biologically active agents. Administration may be systemic or local.

[0144] The pharmaceutical compositions of the present invention can be delivered subcutaneously or intravenously using a standard needle and syringe. Furthermore, for subcutaneous delivery, pen delivery devices are readily useful for delivering the pharmaceutical compositions of the present invention. Such pen delivery devices can be reusable or disposable. Reusable pen delivery devices generally utilize a replaceable cartridge containing the pharmaceutical composition. Once the pharmaceutical composition in the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. Disposable pen delivery devices do not have a replaceable cartridge. Rather, the disposable pen delivery device comes pre-filled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

[0145] A number of reusable pen-type autoinjector delivery devices have utility in the subcutaneous delivery of the pharmaceutical compositions of the present invention. Examples include, but are not limited to, the AUTOPEN TM (Owen Mumford, Inc., Woodstock, UK), DISETRONIC TM Pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75 / 25 TM Pen, HUMALOG TM Pen, HUMALIN 70 / 30 TM Pen (Eli Lilly and Co., Indianapolis, IN), NOVOPEN TMI, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR TM (Novo Nordisk, Copenhagen, Denmark), BD TM Penn (Becton Dickinson, Franklin Lakes, NJ), OPTIPEN TM , OPTIPEN PRO TM , OPTIPEN STARLET TM , and OPTICLIK TM (sanofi-aventis, Frankfurt, Germany). Examples of disposable pen delivery devices that have utility in the subcutaneous delivery of pharmaceutical compositions of the present invention include, but are not limited to, SOLOSTAR TM Pen (sanofi-aventis), FLEXPEN TM (Novo Nordisk), and KWIKPEN TM (Eli Lilly), SURECLICK TM Autoinjector (Amgen, Thousand Oaks, CA), PENLET TM (Haselmeier, Stuttgart, Germany), EPIPEN (Dey, LP), and HUMIRA TM Pen (Abbott Labs, Abbott Park IL) are examples.

[0146] In certain circumstances, pharmaceutical compositions can be delivered in controlled release systems. In one embodiment, pumps can be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201). In another embodiment, polymeric materials can be used; see Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Press, Boca Raton, Florida. In yet another embodiment, controlled release systems can be placed in close proximity to the target of the composition, thus requiring only a fraction of the systemic dose (see, for example, Goodson, 1984, Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527-1533.

[0147] Injectable preparations may include dosage forms for intravenous, subcutaneous, intradermal, and intramuscular injections, infusions, and the like. These injectable preparations can be prepared by known methods. For example, injectable preparations can be prepared by dissolving, suspending, or emulsifying the above-mentioned antibody or a salt thereof in a sterile aqueous or oily medium conventionally used for injections. Aqueous media for injection include, for example, physiological saline, isotonic solutions containing glucose and other adjuvants, and the like, which may be used in combination with appropriate solubilizers such as alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], and the like. Oily media include, for example, sesame oil, soybean oil, and the like, which may be used in combination with solubilizers such as benzyl benzoate, benzyl alcohol, and the like. Therefore, injectable preparations are preferably filled into appropriate ampoules.

[0148] Advantageously, the above-mentioned pharmaceutical compositions for oral or parenteral use are prepared into dosage forms with unit doses suitable for the dose of the active ingredient. Examples of such dosage forms with unit doses include tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of the antibody contained in each dosage form is generally about 5 to about 500 mg per unit dose; particularly, in the form of injections, the antibody is contained in an amount of about 5 to about 100 mg, and for other dosage forms, it is preferably contained in an amount of about 10 to about 250 mg.

[0149] Therapeutic Uses of Antigen-Binding Molecules The present invention includes methods comprising administering to a subject in need thereof a therapeutic composition comprising an anti-CD3 antibody or a bispecific antigen-binding molecule that specifically binds to CD3 and a target antigen (e.g., CD20). The therapeutic composition may comprise any of the antibodies or bispecific antigen-binding molecules disclosed herein and a pharmaceutically acceptable carrier or diluent. As used herein, the phrase "subject in need thereof" means a human or non-human animal that exhibits one or more symptoms or signs of cancer (e.g., a subject that develops a tumor or is afflicted with any of the cancers described herein below) or that would otherwise benefit from inhibition or reduction of CD20 activity or deletion of CD20+ B cells.

[0150] The antibodies and bispecific antigen-binding molecules of the present invention (and therapeutic compositions comprising them) are useful, inter alia, for treating any disease or disorder in which stimulating, activating, and / or targeting an immune response would be beneficial. In particular, the anti-CD3 / anti-CD20 bispecific antigen-binding molecules of the present invention can be used for the treatment, prevention, and / or amelioration of any disease or disorder associated with or mediated by CD20 expression or activity or the proliferation of CD20+ B cells. The mechanism of action by which the therapeutic methods of the present invention are achieved involves the killing of cells expressing CD20 in the presence of effector cells, for example, by CDC, apoptosis, ADCC, phagocytosis, or a combination of two or more of these mechanisms. Cells expressing CD20 that can be inhibited or killed using the bispecific antigen-binding molecules of the present invention include, for example, tumorigenic B cells.

[0151] The antigen-binding molecules of the invention can be used to treat primary and / or metastatic tumors arising in, for example, the brain and meninges, oropharynx, lungs and bronchial tree, gastrointestinal tract, male and female reproductive systems, muscle, bone, skin and adnexa, connective tissue, spleen, immune system, hematopoietic cells and bone marrow, liver and urinary tract, and specialized sensory organs such as the eye. In certain embodiments, the bispecific antigen-binding molecules of the invention are used to treat one or more of the following cancers: renal cell carcinoma, pancreatic cancer, breast cancer, head and neck cancer, prostate cancer, malignant glioma, osteosarcoma, colorectal cancer, gastric cancer (e.g., gastric cancer with MET amplification), malignant mesothelioma, multiple myeloma, ovarian cancer, small cell lung cancer, non-small cell lung cancer, synovial sarcoma, thyroid cancer, or melanoma. According to certain exemplary embodiments, the bispecific antigen-binding molecules of the invention are used to treat one or more of the following cancers: renal cell carcinoma, pancreatic cancer, breast cancer, head and neck cancer, prostate cancer, malignant glioma, osteosarcoma, colorectal cancer, gastric cancer (e.g., gastric cancer with MET amplification), malignant mesothelioma, multiple myeloma, ovarian cancer, small cell lung cancer, non-small cell lung cancer, synovial sarcoma, thyroid cancer, or melanoma. Genotypic binding molecules are used to treat B-cell cancers (e.g., Hodgkin's lymphoma, non-Hodgkin's lymphoma [NHL], precursor B-cell lymphoblastic leukemia / lymphoma, mature B-cell neoplasms, B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma, follicular lymphoma, cutaneous follicle center lymphoma, marginal zone B-cell lymphoma, hairy cell leukemia, diffuse large B-cell lymphoma, Burkitt's lymphoma, plasmacytoma, plasma cell myeloma, post-transplant lymphoproliferative disorder, Waldenstrom's hypergammaglobulinemia, and anaplastic large cell lymphoma).

[0152] According to certain embodiments of the present invention, the antigen binding molecules are useful for treating patients with B-cell lymphoma (e.g., NHL) that are resistant or incompletely responsive to anti-CD20 therapy alone (e.g., resistant to rituximab therapy). According to other related embodiments of the present invention, methods are provided that include administering the anti-CD3 / anti-CD20 bispecific antigen binding molecules disclosed herein to patients with B-cell lymphoma (e.g., NHL) that are refractory to anti-CD20 therapy (e.g., patients with rituximab-refractory tumors or relapsed or refractory B-cell lymphoma). Analytical / diagnostic methods known in the art, such as tumor scanning, can be used to determine whether a patient has a tumor that is resistant, incompletely responsive, or refractory to anti-CD20 therapy alone.

[0153] The present invention also includes methods for treating residual cancer in a subject. As used herein, the term "residual cancer" refers to the presence or persistence of one or more cancer cells in a subject after treatment with an anti-cancer therapy.

[0154] According to certain aspects, the present invention provides methods for treating diseases or disorders associated with CD20 expression (e.g., B-cell lymphoma), comprising administering to a subject one or more of the bispecific antigen-binding molecules described elsewhere herein after the subject has received anti-CD20 monotherapy (e.g., after administration of a pharmaceutical composition comprising an anti-CD20 antibody, such as rituximab). For example, the present invention includes methods for treating B-cell lymphoma, comprising administering to the patient an anti-CD3 / anti-CD20 antigen-binding molecule 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks, 2 months, 4 months, 6 months, 8 months, 1 year, or more after the subject has received anti-CD20 monotherapy (e.g., rituximab treatment or its equivalent). In another aspect, a bispecific antigen-binding molecule of the invention comprising an IgG4 Fc domain (an anti-CD3 / anti-CD20 bispecific antigen-binding molecule) is administered first to a subject at one or more time points (e.g., to effect a steady initial depletion of B cells), followed by administration of an equivalent bispecific antigen-binding molecule comprising a different IgG domain, such as an IgG1 Fc domain, at a later time point.

[0155] Combination Therapies and Formulations The present invention provides methods comprising administering a pharmaceutical composition comprising any of the exemplary antibodies and bispecific antigen-binding molecules described herein in combination with one or more additional therapeutic agents. Exemplary additional therapeutic agents that may be combined or administered in combination with the antigen-binding molecules of the present invention include, for example, an EGFR antagonist (e.g., an anti-EGFR antibody (e.g., cetuximab or panitumumab) or a small molecule inhibitor of EGFR (e.g., gefitinib or erlotinib)), an antagonist of another EGFR family member such as Her2 / ErbB2, ErbB3, or ErbB4 (e.g., an anti-ErbB2, anti-ErbB3, or anti-ErbB4 antibody, or a small molecule inhibitor of ErbB2, ErbB3, or ErbB4 activity), an antagonist of EGFRvIII (e.g., an antibody that specifically binds to EGFRvIII), a cMET agonist (e.g., an antibody that specifically binds to EGFRvIII), a steroid hormone receptor antagonist (e.g., an anti-EGFR antibody (e.g., cetuximab or panitumumab) or a small molecule inhibitor of EGFR (e.g., gefitinib or erlotinib)), an antagonist of another EGFR family member such as Her2 / ErbB2, ErbB3, or ErbB4 (e.g., an anti-ErbB2, anti-ErbB3, or anti-ErbB4 antibody, or a small molecule inhibitor of ErbB2, ErbB3, or ErbB4 activity), an antagonist of EGFRvIII (e.g., an antibody that specifically binds to EGFRvIII), a cMET agonist (e.g., an anti-EGFR antibody ... ) (e.g., anti-cMET antibody), IGF1R antagonist (e.g., anti-IGF1R antibody), B-raf inhibitor (e.g., vemurafenib, sorafenib, GDC-0879, PLX-4720), PDGFR-α inhibitor (e.g., anti-PDGFR-α antibody), PDGFR-β inhibitor (e.g., anti-PDGFR-β antibody), VEGF antagonist (e.g., VEGF-Trap, e.g., US See, for example, US 2009 / 0142354 (also referred to herein as "VEGF-inhibitory fusion proteins"), anti-VEGF antibodies (e.g., bevacizumab), small molecule kinase inhibitors of VEGF receptors (e.g., sunitinib, sorafenib, or pazopanib), DLL4 antagonists (e.g., anti-DLL4 antibodies disclosed in US 2009 / 0142354, such as REGN421), Ang2 antagonists (e.g., anti-Ang2 antibodies disclosed in US 2011 / 0027286, such as H1H685P), FOLH1 antagonists (e.g., anti-FOLH1 antibodies), PRLR antagonists (e.g., anti-PRLR antibodies), STEAP1 or STEAP2 antagonists (e.g., anti-STEAP1 antibodies or anti-STEAP2 antibodies), TMPRSS2 antagonists (e.g., anti-TMPRSS2 antibodies), MSLN antagonists, Antigen-binding molecules of the present invention may also be used in combination with other therapeutic agents, such as cytokine inhibitors (e.g., anti-MSLN antibodies, CA9 antagonists (e.g., anti-CA9 antibodies), uroplakin antagonists (e.g., anti-uroplakin antibodies), and monovalent CD20 antagonists (e.g., monovalent anti-CD20 antibodies such as rituximab). Other agents that may be advantageously administered in combination with the antigen-binding molecules of the present invention include cytokine inhibitors, including small molecule cytokine inhibitors, and antibodies that bind to cytokines such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-11, IL-12, IL-13, IL-17, and IL-18, or their respective receptors. Pharmaceutical compositions of the present invention (e.g., pharmaceutical compositions comprising the anti-CD3 / anti-CD20 bispecific antigen-binding molecules disclosed herein) may also be used in combination with other therapeutic agents, such as "ICE": ifosfamide (e.g., Ifex (R) ), carboplatin (e.g., P Araplatin (R) ), etoposide (e.g., Etopophos (R), Toposar (R) , VePesid (R) , VP-16); "DHAP": dexamethasone (e.g., Decadron (R) ), cytarabine (e.g., Cytosar-U (R) , cytosine arabinoside, ara-C), cisplatin (e.g., Platinol (R) -AQ); and "E SHAP: etoposide (e.g., Etopophos (R) , Toposar (R) , VePesid (R) , VP-16), methylprednisolone (e.g., Medrol (R) ), high-dose cytarabine, cisplatin (e.g., Platinol (R) -AQ) 1 selected The compounds may be administered as part of a therapeutic regimen that includes one or more therapeutic combinations.

[0156] The present invention also includes therapeutic combinations comprising any of the antigen binding molecules mentioned herein and one or more inhibitors of VEGF, Ang2, DLL4, EGFR, ErbB2, ErbB3, ErbB4, EGFRvIII, cMet, IGF1R, B-raf, PDGFR-α, PDGFR-β, FOLH1, PRLR, STEAP1, STEAP2, TMPRSS2, MSLN, CA9, uroplakin, or any of the aforementioned cytokines, wherein the inhibitor is an aptamer, antisense molecule, ribozyme, siRNA, peptibody, nanobody, or antibody fragment (e.g., Fab fragment; F(ab')2 fragment; Fd fragment). Antigen-binding molecules of the present invention may be antibody fragments; Fv fragments; scFv fragments; dAb fragments; or other engineered molecules such as diabodies, triabodies, tetrabodies, minibodies, and minimal recognition units. The antigen-binding molecules of the present invention may also be administered in combination with and / or co-formulated with antivirals, antibiotics, analgesics, corticosteroids, and / or NSAIDs. The antigen-binding molecules of the present invention may also be administered as part of a treatment regimen that also includes radiation treatment and / or conventional chemotherapy.

[0157] The additional therapeutically active ingredient may be administered immediately before, simultaneously with, or immediately after the administration of the antigen-binding molecule of the present invention. (For the purposes of this disclosure, such a dosing regimen will be considered administration of the antigen-binding molecule "in combination" with the additional therapeutically active ingredient).

[0158] The present invention includes pharmaceutical compositions in which the antigen-binding molecules of the invention are co-formulated with one or more additional therapeutically active ingredients, as described elsewhere herein.

[0159] Dosage regimen According to certain embodiments of the present invention, multiple doses of an antigen-binding molecule (e.g., an anti-CD3 antibody or a bispecific antigen-binding molecule that specifically binds to CD20 and CD3) may be administered to a subject over a defined time course. A method according to this aspect of the present invention comprises sequentially administering multiple doses of an antigen-binding molecule of the present invention to a subject. As used herein, "sequentially administering" means that each dose of the antigen-binding molecule is administered to a subject at different time points, for example, on different days separated by a predetermined interval (e.g., hours, days, weeks, or months). The present invention includes methods comprising sequentially administering a single initial dose of the antigen-binding molecule, followed by one or more secondary doses of the antigen-binding molecule, and optionally followed by one or more tertiary doses of the antigen-binding molecule.

[0160] The terms "initial dose," "secondary dose," and "tertiary dose" refer to the time sequence of administration of an antigen-binding molecule of the present invention. Thus, an "initial dose" is a dose administered at the beginning of a treatment regimen (also referred to as a "baseline dose"); a "secondary dose" is a dose administered after the initial dose; and a "tertiary dose" is a dose administered after the secondary dose. The initial, secondary, and tertiary doses may all contain the same amount of antigen-binding molecule, but generally may differ from each other in terms of administration frequency. However, in certain embodiments, the amount of antigen-binding molecule contained in the initial, secondary, and / or tertiary doses varies from each other during the course of treatment (e.g., adjusted upward or downward as appropriate). In certain embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered as a "loading dose" at the beginning of a treatment regimen, followed by subsequent doses (e.g., maintenance doses) administered at a less frequent frequency.

[0161] In one exemplary embodiment of the invention, the secondary and / or tertiary doses are each administered 1 to 26 weeks (e.g., 1, 1 1 / 2, 2, 2 1 / 2, 3, 3 1 / 2, 4, 4 1 / 2, 5, 5 1 / 2, 6, 6 1 / 2, 7, 7 1 / 2, 8, 8 1 / 2, 9, 9 1 / 2, 10, 10 1 / 2 , 11, 11 1 / 2, 12, 12 1 / 2, 13, 13 1 / 2, 14, 14 1 / 2, 15, 15 1 / 2, 16, 16 1 / 2, 17, 17 1 / 2, 18, 18 1 / 2, 19, 19 1 / 2, 20, 20 1 / 2, 21, 21 1 / 2, 22, 22 1 / 2, 23, 23 1 / 2, 24, 24 1 / 2, 25, 251 / 2, 26, 26 1 As used herein, the phrase "immediately preceding the dose" refers to a dose of an antigen-binding molecule administered to a patient prior to the administration of the next dose in the sequence, without any intervening doses, in a series of multiple doses.

[0162] The method according to this aspect of the invention can include administering any number of secondary and / or tertiary doses of an antigen-binding molecule (e.g., an anti-CD3 antibody or a bispecific antigen-binding molecule that specifically binds to CD20 and CD3) to a patient. For example, in certain embodiments, only a single secondary dose is administered to a patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to a patient. Similarly, in certain embodiments, only a single tertiary dose is administered to a patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to a patient.

[0163] In embodiments involving multiple secondary doses, each secondary dose can be administered as frequently as the other secondary doses. For example, each secondary dose can be administered to the patient 1-2 weeks after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose can be administered as frequently as the other tertiary doses. For example, each tertiary dose may be administered to a patient 2 to 4 weeks after the immediately preceding dose. Alternatively, the frequency with which the secondary and / or tertiary doses are administered to a patient may vary during the treatment regimen. The frequency of administration may also be adjusted during the course of treatment by a physician depending on the needs of the individual patient after clinical testing.

[0164] Diagnostic Uses of Antibodies The anti-CD3 antibodies of the present invention can also be used to detect and / or measure CD3 or cells expressing CD3 in a sample, e.g., for diagnostic purposes. For example, anti-CD3 antibodies, or fragments thereof, can be used to diagnose conditions or diseases characterized by abnormal expression of CD3 (e.g., overexpression, underexpression, lack of expression, etc.). An exemplary diagnostic assay for CD3 can include, for example, contacting a sample obtained from a patient with an anti-CD3 antibody of the present invention, where the anti-CD3 antibody is labeled with a detectable label or reporter molecule. Alternatively, an unlabeled anti-CD3 antibody can be used in diagnostic applications in combination with a secondary antibody that is itself detectably labeled. The detectable label or reporter molecule can be a radioisotope, e.g., 3 H, 14 C. 32 P, 35 S, or 125 The CD3 antibody may be a fluorescent or chemiluminescent moiety, such as fluorescein isothiocyanate or rhodamine; or an enzyme, such as alkaline phosphatase, beta-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure CD3 in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence-activated cell sorting (FACS).

[0165] Samples that can be used in CD3 diagnostic assays according to the present invention include any tissue or fluid sample obtainable from a patient and contain detectable amounts of CD3 protein or fragments thereof under normal or pathological conditions. Generally, the level of CD3 in a particular sample obtained from a healthy patient (e.g., a patient not suffering from a disease or condition associated with abnormal CD3 levels or activity) is first measured to establish a baseline, or standard, level of CD3. This baseline level of CD3 can then be compared to the CD3 level measured in a sample obtained from an individual suspected of having a CD3-related disease or condition. [Example]

[0166] The following examples are presented so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric.

[0167] Example 1. Generation of anti-CD3 antibodies Anti-CD3 antibody was administered via VELOCIMMUNE (R) Mouse (i.e., human immunoglobulin Antibody immune responses were obtained by immunizing mice (manipulated mice containing DNA encoding heavy and kappa light chain variable regions) with cells expressing CD3 or DNA encoding CD3. Antibody immune responses were monitored by CD3-specific immunoassays. When the desired immune response was achieved, splenocytes were harvested and fused with mouse myeloma cells to preserve their viability and form hybridoma cell lines. The hybridoma cell lines were screened and selected to identify cell lines producing CD3-specific antibodies. Using this technique, several anti-CD3 chimeric antibodies (i.e., antibodies with human variable domains and mouse constant domains) were obtained. Furthermore, several fully human anti-CD3 antibodies were generated directly from antigen-positive B cells without fusion to myeloma cells, as described in US 2007 / 0280945A1. It was isolated.

[0168] The specific biological properties of exemplary anti-CD3 antibodies produced according to the methods of this example are described in detail in the Examples set forth below.

[0169] Example 2. Heavy and Light Chain Variable Region Amino Acid and Nucleic Acid Sequences Table 1 shows the amino acid sequence identifiers of the heavy and light chain variable regions and CDRs of selected anti-CD3 antibodies of the invention. The corresponding nucleic acid sequence identifiers are shown in Table 2.

[0170] [Table 1]

[0171] [Table 2]

[0172] [Table 3]

[0173] [Table 4]

[0174] [Table 5]

[0175] Antibodies are typically referred to herein according to the following nomenclature: an Fc prefix (e.g., "H1H," "H1M," "H2M," etc.), followed by a numerical identifier (e.g., "2712," "2692," etc., as shown in Table 1), followed by a "P," "N," or "B" suffix. Thus, according to this nomenclature, antibodies are referred to herein as, for example, "H1H2 712N," "H1M2692N," "H2M2689N," etc. The prefixes H1H, H1M, and H2M in the antibody names used herein indicate the specific Fc region isotype of the antibody. For example, an "H1H" antibody has a human IgG1 Fc, an "H1M" antibody has a murine IgG1 Fc, and an "H2M" antibody has a murine IgG2 Fc (all variable regions are fully human, as indicated by the initial "H" in the antibody name). Those skilled in the art will appreciate that an antibody having a particular Fc isotype can be converted to an antibody having a different Fc isotype (e.g., an antibody having a murine IgG1 Fc can be converted to an antibody having a human IgG4 Fc), but in either case, the variable domains (including the CDRs)—indicated by the numerical identifiers shown in Table 1—remain the same, and the binding characteristics are expected to be the same or substantially similar regardless of the nature of the Fc domain.

[0176] Control constructs used in the following examples Various control constructs (anti-CD3 antibodies) were included in the following experiments for comparison purposes: OKT-3 ", a mouse monoclonal antibody against a human T-cell surface antigen available from the American Type Culture Collection (ATCC) under catalog number CRL-8001; and " SP34 ”, reactive against the epsilon chain of the T3 complex on human T lymphocytes, Biolegend, San A commercially available mouse monoclonal antibody obtained from San Diego, CA (Cat. No. 302914).

[0177] Example 3. Binding Affinity and Rate Constants of Human Monoclonal Anti-CD3 Antibodies Derived by Surface Plasmon Resonance The binding affinities and kinetic constants of human monoclonal anti-CD3 antibodies were determined by surface plasmon resonance at 25° C. using either an antibody capture format (Tables 3, 5, and 7) or an antigen capture format (Tables 4, 6, and 8). Measurements were performed on a T200 Biacore instrument.

[0178] In the antibody capture format, the Biacore sensor surface was derivatized with rabbit anti-mouse Fc (antibody prefix H1M or H2M) for hybridoma capture or mouse anti-human Fc surface for human IgG format antibodies (antibody prefix H1H). Soluble heterodimeric CD3 proteins (hCD3-epsilon / hCD3-delta; SEQ ID NOs: 1370 / 1371) bearing either a human Fc tag (hFcΔAdp / hFc; SEQ ID NOs: 1372 / 1373) or a mouse Fc tag (mFcΔAdp / mFc; SEQ ID NOs: 1374 / 1375) were injected over the antibody-captured surface, and the binding response was recorded. The heterodimeric CD3 proteins were purified using the method described in Davis et al. (US2010 / 0331527).

[0179] In the antigen capture format, the heterodimeric CD3 protein was captured using rabbit anti-mouse Fc or mouse anti-human Fc, and the respective antibodies were injected over the captured antigen.

[0180] The antibodies were analyzed in their traditional bivalent format (Tables 3-6) or in a monovalent one-arm configuration in which the second Fab was removed from the antibody and only the Fc portion (CH2-CH3) was expressed (Tables 7 or 8).

[0181] Dynamic coupling (k a ) and dissociation (k d The binding-dissociation equilibrium constant (K) was determined by processing the data and fitting to a 1:1 binding model using Scrubber 2.0 curve fitting software. D ) and dissociation half-life (t 1 / 2 ) was calculated from the kinetic rate constant as follows: K D (M)=k d / k a ; and t 1 / 2 (min)=(ln2 / (60 * k d ). NT = not tested; NB = no binding observed.

[0182] [Table 6]

[0183] [Table 7]

[0184] [Table 8]

[0185] [Table 9]

[0186] [Table 10]

[0187] [Table 11]

[0188] As shown in Tables 3-8, several anti-CD3 antibodies of the invention bind to CD3 with high affinity in either antibody-capture or antigen-capture formats.

[0189] Example 4. Anti-CD3 antibodies bind and proliferate human T cells Anti-CD3 antibodies of the invention were tested for their ability to bind to and induce proliferation of human T cells. Binding was assessed using Jurkat cells (a CD3+ human T cell line), and proliferation of peripheral blood mononuclear cells (PBMCs) was measured using an ATP-catalyzed assay (CellTiter Glo). (R) The anti-CD3 antibody OKT3 served as a positive control. , and a corresponding antibody of irrelevant isotype served as a negative control.

[0190] FACS data were obtained using the following protocol: 2x10 per well 5 Individual details Cells were incubated with serially diluted antibodies for 30 minutes on ice. Afterwards, cells were washed and secondary antibody was added and incubated for an additional 30 minutes. After incubation, cells were washed, resuspended in cold PBS containing 1% BSA, and analyzed by flow cytometry, gating on side and forward scatter for viable Jurkat cells. EC for cell-binding titration 50 was determined using Prism software with values ​​calculated using four-parameter nonlinear regression analysis.

[0191] Proliferation data were obtained using the following protocol: human PBMCs (5x10 4 / well) The cells were incubated with 3-fold serial dilutions of anti-CD3 and a fixed concentration of a commercially available anti-CD28 antibody (200 ng / ml) in a 96-well plate for 72 hours at 37°C. After incubation, the cells were analyzed using CellTiter Glo (R) Add the VICTOR X5 multi-color lighting. Cell viability was measured using a Chirabel plate reader (PerkinElmer). 50 (ATP catalytic quantitation) was calculated using four-parameter nonlinear regression analysis in GraphPad Prism.

[0192] The results of the binding and proliferation experiments are summarized in Tables 9-11.

[0193] [Table 12]

[0194] [Table 13]

[0195] [Table 14]

[0196] As shown in Tables 7 to 9, most of the anti-CD3 antibodies of the present invention bound to human T cells and induced T cell proliferation.

[0197] Example 5. Anti-CD3 antibodies bind to and proliferate monkey T cells A subset of the anti-CD3 antibodies of the invention were tested for their ability to bind to and induce proliferation of monkey T cells.

[0198] FACS data were obtained using the following protocol: 2x10 per well 5 Individual details Cells were incubated with serially diluted antibodies for 30 minutes on ice. After incubation, cells were washed, and secondary antibodies were added and incubated for an additional 30 minutes. After incubation, cells were washed, resuspended in cold PBS containing 1% BSA, and analyzed by flow cytometry. CD4+ monkey T cells were gated by side and forward scatter and on the CD2+CD4+CD20- population. EC values ​​were calculated for cell-binding titration using a four-parameter nonlinear regression analysis in GraphPad Prism. 50 was calculated.

[0199] Proliferation data were obtained using the following protocol: freshly isolated cynomolgus monkey-derived P BMC(5x10 4 / well) were diluted 3-fold with serial dilutions of anti-CD3 antibody and a fixed concentration of commercially available anti-CD3 antibody. The cells were incubated with CD28 antibody (500 ng / ml) in a 96-well plate for 72 hours at 37°C. After incubation, the cells were analyzed using CellTiter Glo (R) Add The luminescence was measured using a VICTOR X5 multilabel plate reader (PerkinElmer). 50 (ATP catalytic quantitation) was calculated using four-parameter nonlinear regression analysis in GraphPad Prism.

[0200] The results of the binding and proliferation experiments are summarized in Tables 12 and 13.

[0201] [Table 15]

[0202] [Table 16]

[0203] As shown in Tables 12 and 13, several anti-CD3 antibodies of the present invention bound to and induced proliferation of CD2+CD4+ monkey T cells. OKT3 did not drive monkey PBMC proliferation, but SP34 was active against monkey PBMC.

[0204] Example 6. Anti-CD3 mAb supports T cell-mediated killing of tumor cells The ability of anti-CD3 antibodies to redirect T cell-mediated killing through Fc / FcR interactions was tested using a calcein-based U937 killing assay. Briefly, human PBMCs were isolated with Ficoll-Paque and activated for several days with medium containing human IL-2 (30 U / ml) and T cell activation beads (anti-CD3 / CD28). U937 cells were labeled with calcein and then incubated with activated T cells using 3-fold serial dilutions of antibodies at a 10:1 effector:target ratio for 3 hours at 37°C. After incubation, plates were centrifuged, and supernatants were transferred to translucent black, clear-bottom plates for fluorescence analysis. EC2, defined as the molar concentration of CD3 antibody that induces 50% cytotoxicity, was determined. 50 Values ​​were calculated using four-parameter nonlinear regression analysis in GraphPad Prism. Results using hybridoma antibodies, human Fc antibodies, and monovalent one-arm antibodies are shown in Tables 14, 15, and 16, respectively.

[0205] [Table 17]

[0206] [Table 18]

[0207] [Table 19]

[0208] As shown in Tables 14-16, most anti-CD3 antibodies, as well as OKT3, supported redirected T cell-mediated killing in this assay system. The observed killing, which is thought to be dependent on Fc engagement of the antibody with Fc receptors on U937 cells, leading to clustering of CD3 on adjacent T cells, was suppressed by the addition of nonspecific human IgG (data not shown).

[0209] Example 7. Generation of bispecific antibodies that bind to CD3 and CD20 Bispecific antibodies comprising anti-CD3-specific binding domains and anti-CD20-specific binding domains were constructed using standard methodologies. Here, heavy and light chains from an anti-CD3 antibody were combined with a heavy chain from an anti-CD20 antibody. The anti-CD3 antibody used to construct the bispecific antibodies in this example was transfected with VelocImmune using cells expressing CD3 or DNA encoding CD3. (R) by immunizing mice or BS3 / 20-00 In the case of -009 and -007, the antibodies were derived from known anti-CD3 antibodies (i.e., the anti-CD3 antibody "L2K" described in WO2004 / 106380). The anti-CD20 antibody used to construct the bispecific antibody of this example is described in US Pat. No. 7,879,984.

[0210] The bispecific antibodies produced according to this example comprise two separate antigen-binding domains (i.e., binding arms). The first antigen-binding domain is a light chain variable region derived from an anti-CD3 antibody. The first antigen-binding domain comprises a heavy chain variable region ("CD20-VH") from an anti-CD20 antibody paired with a light chain variable region ("CD3-VL") from an anti-CD3 antibody. The CD20-VH / CD3-VL pairing generates an antigen-binding domain that specifically recognizes CD20. The second antigen-binding domain comprises a heavy chain variable region ("CD3-VH") from an anti-CD3 antibody paired with a light chain variable region ("CD3-VL") from an anti-CD3 antibody. The CD3-VH / CD3-VL pairing generates an antigen-binding domain that specifically recognizes CD3. The same CD20-VH was used in all bispecific antibodies generated in this example and is referred to as "CD20-VH-A" (except for BS3 / 20-009, which used a different CD20-VH and is referred to as "CD20-VH-B"). However, several different CD3-VH and CD3-VL components (termed CD3-VH-A, CD3-VH-B, etc., and CD3-VL-A, CD3-VL-B, etc., and derived from different anti-CD3 antibodies) were used in the different bispecific antibodies of the following examples.

[0211] A summary of the components of the antigen-binding domains of the various bispecific antibodies generated according to this example is shown in Table 17.

[0212] [Table 20]

[0213] Tables 18 and 19 show the amino acid sequence identifiers of the various heavy chain variable regions (Table 18) and light chain variable regions (Table 19) of the bispecific antibodies of this example and their corresponding CDRs.

[0214] [Table 21]

[0215] [Table 22]

[0216] Additionally, Tables 20 and 21 provide sequence identifiers for the nucleotide sequences encoding the heavy chain variable regions (Table 20) and light chain variable regions (Table 21) of the bispecific antibodies of this example, and their corresponding CDRs.

[0217] [Table 23]

[0218] [Table 24]

[0219] In addition to the bispecific antibodies described above, the following control antibodies were also used in some of the experiments shown in the Examples below: Control I : "OKT-3," a monoclonal antibody against a human T-cell surface antigen, described in US Pat. No. 4,361,549 and available from hybridoma CRL-8001 (American Type Culture Collection, Manassas, VA). Control II : "SP34," an antibody reactive with the epsilon chain of the T3 complex on human T lymphocytes, available from BD Pharmagen, catalog number 55052. Control III :An anti-CD20 therapeutic antibody having the heavy and light chain sequences of Rituxan (rituximab) as disclosed in US 5,736,137. Control IV A monoclonal anti-CD20 antibody designated "3B9-10", disclosed in US Pat. No. 7,879,984 and designated herein as an antibody comprising the HCVR / LCVR amino acid sequence pair of SEQ ID NOs: 1242 / 1346 and the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence of SEQ ID NOs: 1244-1246-1248-1348-1350-1352. Control VA monoclonal anti-CD20 antibody designated "10F2-13" as disclosed in US 7,879,984 and designated herein as an antibody comprising the HCVR / LCVR amino acid sequence pair of SEQ ID NOs: 1354 / 1362 and the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence of SEQ ID NOs: 1356-1358-1360-1364-1366-1368.

[0220] Example 8. CD20xCD3 bispecific antibodies selectively bind to Jurkat, Raji, and monkey T cells The CD20xCD3 bispecific antibody and control constructs shown in Example 1 were tested by FACS for their ability to bind to Jurkat (a CD3+, CD20- human T cell line), Raji (a CD3-, CD20+ human B cell line), or cynomolgus monkey PBMCs ("mkT cells").

[0221] FACS data were obtained using the following protocol: 2x10 cells per well 5 Cells were incubated with serially diluted antibodies for 30 minutes on ice. After incubation, cells were washed, and the appropriate secondary (Jurkat, Raji cells) or cocktail of secondary antibodies (for cynomolgus monkey PBMCs) was added and incubated for an additional 30 minutes. After incubation, cells were washed, resuspended in cold PBS containing 1% BSA, and analyzed by flow cytometry on a BD FACS Canto II. Jurkat and Raji cells were gated by side and forward scatter, and cynomolgus monkey T cells were also gated on the CD2+CD4+ population. EC for cell-binding titration 50 was determined using values ​​calculated using four-parameter nonlinear regression analysis using Prism software. The results are shown in Table 22.

[0222] [Table 25]

[0223] As shown in Table 22, the panel of tested antibodies exhibits various binding affinities for various cell lines depending on their specificity. Bispecific antibodies (BS3 / 20-001, -002, -003, -004, and -005) demonstrated the ability to bind to both human target lines. A subset of antibodies also demonstrated the ability to bind to cynomolgus monkey cells (Control II, BS3 / 20-001, and BS3 / 20-003). Anti-CD3 Control I (OKT3), anti-CD3 Control II (SP34), and anti-CD20 Control IV bound to Jurkat, cynomolgus monkey T cells, and RAJI, respectively.

[0224] Example 9. CD20xCD3 bispecific antibodies induce PBMC proliferation in vitro The ability of selected CD20xCD3 bispecific antibodies and control constructs to stimulate peripheral blood mononuclear cells (PBMCs) to induce proliferation was assessed using an ATP-catalyzed assay (CellTiter Glo (R) Activation of PBMCs results in the release of cytokines, which drive cell proliferation.

[0225] Proliferation data were obtained using the following protocol: PBMCs (5x10) from humans or cynomolgus monkeys 5 / well) along with 3-fold serial dilutions of anti-CD3xCD20 or control antibody The cells were incubated in a 96-well plate for 72 hours at 37°C. After incubation, the cells were incubated with CellTiter Glo (R) Add the VICTOR X5 Multi-Label and light up the The EC values ​​for cell viability were measured using a plate reader (PerkinElmer). 50 (ATP catalytic quantitation) was determined using Prism software. Values ​​were calculated using four-parameter nonlinear regression analysis and are shown in Table 23.

[0226] [Table 26]

[0227] As shown in Table 23, all CD20xCD3 bispecific antibodies of the invention were activators of human or cynomolgus monkey PBMCs. In general, the anti-CD3 monospecific bivalent parent antibodies (Controls I and II) were 2- to 10-fold more potent than their bispecific counterparts. Control I (OKT3) did not drive monkey PBMC proliferation, while Control II (SP34) was active against both human and monkey PBMCs.

[0228] Example 10. CD20xCD3 bispecific antibodies activate T cells in human whole blood and induce IFN-gamma release and CD25 upregulation Selected CD20xCD3 bispecific antibodies were tested for their ability to activate T cells in human whole blood. The extent of T cell activation was determined by measuring interferon-gamma (IFNγ) secretion as well as upregulation of CD25 on CD8+ T cells.

[0229] Interferon-gamma (IFNγ) secretion was quantified by mixing heparinized whole blood with 5-fold serial dilutions of bispecific antibodies in 96-well plates. After 20 hours, plates were centrifuged for 5 minutes, and plasma was removed for ELISA analysis to determine IFNγ levels. Estimated IFNγ concentrations were plotted against antibody concentrations, and EC 50 Values ​​were calculated using four-parameter nonlinear regression analysis using Prism software.

[0230] For analysis of CD25 expression on CD8+ T cells, after incubation with antibodies and removal of plasma, 150 μl of blood was transferred to a deep-well plate and 1.5 mL RBCs were lysed for 15 minutes using RBC lysis buffer. Cells were washed twice, blocked for 10 minutes at room temperature using hFcR blocking reagent, and then incubated for 30 minutes at 4°C with antibodies directly conjugated to CD2, CD19, CD4, CD8, and CD25. Cells were then washed twice and analyzed using a FACSCanto cytometer and FlowJo software.

[0231] The percentage of CD2+CD8+ T cells expressing the activation marker CD25 was plotted against antibody concentration, and EC 50 Values ​​were calculated using four-parameter nonlinear regression analysis using Prism software. The results are shown in Table 24.

[0232] [Table 27]

[0233] As shown in Table 24, the CD20xCD3 bispecific antibodies had EC values ​​ranging from 130 to 290 pM. 50 mediated upregulation of CD25 on CD8+ T cells in whole blood and the corresponding EC for IFNγ. 50 The values ​​were slightly higher, ranging from 390 pM to 2 nM. BS3 / 20-004 had an EC 50 BS3 / 20-004 was able to induce higher levels of IFNγ in whole blood cultures, while BS3 / 20-001 and BS3 / 20-003 were then slightly less potent in mediating CD25 upregulation and IFNγ production as determined by ELISA.

[0234] Example 11. CD20xCD3 bispecific antibodies induce T cell-mediated cytotoxicity in rituximab-resistant cell lines The ability of selected CD20xCD3 bispecific antibodies and control constructs to mediate complement-dependent cytotoxicity (CDC) and T cell-mediated cytotoxicity was evaluated using parental Raji cells and Raji SCID lines. The latter (Raji SCID lines) were derived from individual anti-CD20-resistant tumors isolated from immunodeficient mice that had been treated with the anti-CD20 mAb rituximab followed by subcutaneous injection of Raji cells. Four lines (Raji SCID 1-4) were used in this example.

[0235] The expression of CD20 and the complement inhibitory molecules CD55 and CD59 in the Raji cell line was determined by FACS. 6Cells were incubated in individual tubes for 30 min at 4°C. The cells were incubated with antibodies directly conjugated to D20, CD55, and CD59. After washing the cells twice, FACS was acquired using a FACSCanto cytometer and analyzed with FlowJo software.

[0236] To determine the ability of anti-CD20 and anti-CD3xCD20 antibodies to mediate T cell-directed killing of the Raji cell line, calcein-labeled Raji cells were incubated with pre-activated T cells (Ficoll-isolated human PBMCs activated with rhIL-2 (30 U / mL) and anti-CD3 / CD28 activation beads) and 3-fold serial dilutions of antibodies starting at 2 nM for 2 hours at 37°C. After incubation, plates were centrifuged, and supernatants were transferred to semi-transparent black clear-bottom plates for 530 nm fluorescence detection with 485 nm emission. Percent cytotoxicity was determined based on spontaneous (target cells only) and maximum release (detergent-lysed target cells) values. EC 50 Values ​​were calculated using four-parameter nonlinear regression analysis using Prism software.

[0237] To determine the ability of the antibodies to mediate CDC, the Raji cell line was incubated with 5% normal human serum complement and serial 3-fold dilutions of the antibodies starting at 100 nM. After 4.5 hours of incubation at 37°C, the cells were analyzed using CellTiter Glo. (R) Cell Death Using Percent cytotoxicity was determined based on spontaneous (target cells only) and maximum release (surfactant). The EC values ​​were determined based on the target cells lysed at 1000 s.c. 50 Values ​​were calculated using four-parameter nonlinear regression analysis using Prism software.

[0238] The results are shown in Table 25.

[0239] [Table 28]

[0240] Compared with parental Raji cells, two of the four Raji SCID lines showed reduced expression of CD20 (Table 25; lines Raji SCID 1 and 3), and a significantly higher percentage of cells expressed the complement inhibitory molecules CD55 and CD59. The susceptibility of Raji SCID cells to CDC mediated by either anti-CD20 or anti-CD20xCD3 antibodies depended on the percentage of CD55 / CD59-expressing cells, but not on the level of CD20, such that increased expression of CD55 / CD59 on target cells inhibited CDC.

[0241] The anti-CD20 antibodies (Control IV and Control III [Rituximab]) were more potent than anti-CD20xCD3 (BS3 / 20-007) in mediating CDC because the bispecifics are monovalent for CD20. However, in contrast to CDC, T cell-mediated cytotoxicity was not dependent on CD20 levels or CD55 / CD59, since all cell lines were equally susceptible to cell death by activated T cells in the presence of the anti-CD20xCD3 bispecific antibody. Furthermore, the bispecific antibody was 100- to 1000-fold more potent in mediating T cell-dependent killing of Raji cells than the anti-CD20 antibody in the CDC assay.

[0242] Example 12. CD25 upregulation on CD8+ T cells is dependent on CD20 concentration in the presence of CD20xCD3 bispecific antibodies To assess whether a higher concentration of target cells (CD20+ lymphoma) results in increased efficacy of the CD20xCD3 bispecific antibody, human peripheral blood mononuclear cells (PBMCs) were co-cultured in the presence of a Burkitt's lymphoma-derived cell line, Raji.

[0243] CD25 upregulation on CD8+ T cells was determined using the following protocol: human PBMCs (5x10) isolated by centrifugation of mononuclear cell-enriched leukocyte-depleted blood with Ficoll. 5 / mL) in the presence of Raji cells (1 x 10 51 mL) or in the absence of 5-fold serial dilutions of bispecific antibodies in 96-well flat-bottom plates at 37°C. After 48 hours, cells were washed twice and blocked with hFcR blocking reagent at room temperature. The cells were blocked for 10 minutes and then incubated with antibodies directly conjugated to CD2, CD19, CD4, CD8, and CD25 for 30 minutes at 4°C. After staining, the cells were washed twice and then FACS was acquired using a FACSCanto cytometer and analyzed using FlowJo software. The percentage of activated CD2+CD8+ T cells expressing CD25 was plotted against antibody concentration, and EC 50 Values ​​were calculated using four-parameter nonlinear regression analysis using Prism software. The results are shown in Table 26.

[0244] [Table 29]

[0245] As shown in Table 26, activated T cells when cultured in the presence of Raji (target) cells upregulated CD25, and subsequently their EC 50 showed a 100-fold decrease in values.

[0246] Example 13. CD20xCD3 bispecific antibody induces cytotoxicity against Raji cells in the presence of activated T cells The ability of the CD20xCD3 bispecific antibody to redirect T cell-mediated killing to CD20-expressing Raji cells was tested in an in vitro cytotoxicity assay. Additionally, the ability of both the bispecific and parental anti-CD3 antibodies to kill U937 cells via Fc / FcR interactions was also examined.

[0247] Calcein killing assays were performed using the following protocol: Human and cynomolgus monkey PBMCs were isolated with Ficoll-Plaque or Lympholyte Mammal cell separation medium, respectively. Isolated PBMCs were activated for several days with medium containing recombinant human IL-2 (30 U / ml) and T cell activation beads (anti-CD3 / CD28 for human PBMCs and anti-CD2 / CD3 / CD28 for cynomolgus monkey PBMCs).

[0248] Target cells (Raji for CD20-mediated killing and U937 for FcR-mediated killing) were labeled with calcein and incubated with activated T cells using 3-fold serial dilutions of antibodies at a 10:1 effector:target ratio for 3 hours at 37°C. After incubation, plates were centrifuged and supernatants were transferred to semi-transparent black clear-bottom plates for fluorescence analysis. EC2, defined as the molar concentration of bispecific antibody that induces 50% cytotoxicity, was measured. 50 was determined using Prism. Values ​​were calculated using four-parameter nonlinear regression analysis. Results are summarized in Table 27.

[0249] [Table 30]

[0250] As shown in Table 27, bispecific CD20xCD3 antibodies containing human-specific or human / cynomolgus monkey cross-reactive anti-CD3 arms were able to specifically redirect cytotoxicity to Raji cells in the presence of human activated T cells. Raji cells were killed when incubated with BS3 / 20-001 or BS3 / 20-003, bispecific antibodies with anti-CD3 arms that activate monkey T cells, in the presence of cynomolgus monkey activated T cells. All bispecific antibodies, as well as control I, an anti-CD3 mAb, showed activity in the U937 Fc / FcR-dependent killing assay. This activity could be blocked by adding a blocking nonspecific human IgG to the reaction (data not shown).

[0251] Example 14. CD3xCD20 bispecific antibodies can deplete CD19+ B cells in mice reconstituted with human immune cells To determine the in vivo efficacy of CD3xCD20 bispecific antibody administration, CD19+ Changes in B cell and CD2+ T cell levels were examined by FACS after administration of 10 μg or 0.1 μg of anti-CD3xCD20 bispecific antibody to mice reconstituted with human immune cells.

[0252] Briefly, newborn BALB / Rag2 null / ( c null Mice were irradiated with 2x150 rads and 4x10 5 Human CD34 + Hematopoietic progenitor cells were reconstituted by intrahepatic injection. After 12 weeks, the composition of the reconstituted human immune system in peripheral blood was determined by flow cytometry. Typically, by 3 months after reconstitution, between 10% and 60% of peripheral leukocytes were human CD45+, of which 40% to 70% were B cells, 15% to 40% were T cells, and the remainder were small populations of natural killer cells and dendritic cells.

[0253] Five months after reconstitution, mice were injected intraperitoneally with 10 μg or 0.1 μg of the anti-CD3xCD20 bispecific antibody BS3 / 20-007, 10 μg of a monovalent one-arm CD3 antibody (BS3 / 20-009, see Table 1), or 10 μg of an irrelevant hIgG isotype control. At 1, 8, and 25 days after injection, retro-orbital bleeds were performed, and immune cell counts in the peripheral blood were determined by flow cytometry (FACS).

[0254] For FACS analysis, 100 μl of blood was incubated with 1.5 ml RBC lysis buffer in an Eppendorf tube for 3 minutes. Cells were centrifuged for 5 minutes at 0.4 × g, washed twice with FACS wash solution (PBS + 3% FBS), and blocked for 10 minutes with mouse Fc blocking reagent at room temperature. Cells were then directly probed for CD2, CD3, CD19, CD4, CD8, hCD45, hHLA-DR, and mCD45 for 30 minutes at 4°C. The cells were incubated with covalently conjugated antibodies. After staining, the cells were washed twice and then FACS was acquired using a FACSCanto cytometer and analyzed using FlowJo software. The results are shown in Table 28.

[0255] [Table 31]

[0256] As shown in Table 28, a single 10 μg dose of the anti-CD3xCD20 bispecific antibody BS3 / 20-007 resulted in a loss of circulating hCD45+ cells in two of two treated mice, which did not recover throughout the experiment. A single 0.1 μg dose of BS3 / 20-007 reduced circulating hCD45+ cells (including CD19+ B cells and CD2+ T cells) 24 hours after injection in two of three treated mice. Once depleted, the percentage of hCD45+ cells did not significantly recover in responder mice treated with 0.1 μg BS3 / 20-007. However, the remaining cells in these mice were primarily hCD2+ T cells, and CD19+ B cells were absent in responder mice even 25 days after treatment. A single 10 μg dose of a monovalent one-arm CD3 antibody (BS3 / 20-009) also produced a sustained but modest reduction in CD45+ cells, particularly CD2+ T cells, in two of two treated mice. A single 10 μg dose of an irrelevant hIgG1 control had no significant effect on the percentage of circulating hCD45+, hCD19+, or hCD2+ cells.

[0257] Example 15. Treatment with CD20xCD3 bispecific antibody reduces Raji tumor volume in NOD / SCID mice To evaluate the efficacy of selected anti-CD3xCD20 bispecific antibodies in reducing Raji tumor growth, 2x10 6 Ra ji tumor cells and 8x10 6 A mixture of human PBMCs was subcutaneously implanted. Mice were treated with either CD3xCD20 bispecific antibody (BS3 / 20-007) or CD3xCD20 bispecific antibody (BS3 / 20-007) at a dose of 1 μg per mouse, three times a week starting from the day of tumor implantation (N=20 mice per treatment group). The reagents were delivered by intraperitoneal (ip) injection. Tumor size was measured by NIH. Tumor volumes were measured three times per week using a CT scan, and tumor volumes were calculated as volume = (length x width). 2 ) / 2 The results are shown in Figure 1.

[0258] In a second experiment, NOD / SCID mice were given 2x10 6 Raji tumor cells and and 4x10 6 A mixture of human PBMCs was subcutaneously implanted. Treatment with the antibody (BS3 / 20-007) or control reagent (hFc) began 7 days after tumor implantation, when tumors were palpable. Mice were treated twice weekly at a dose of 1 μg per mouse (N=6 mice per treatment group). Reagents were injected subcutaneously, away from the tumor implantation site. Tumor size was measured twice weekly using calipers, and tumor volume was calculated as volume = (length x width). 2 ) / The calculation was made as 2. The results are shown in Figure 2.

[0259] This example demonstrates that treatment with the CD3xCD20 bispecific antibody BS3 / 20-007 was effective in inhibiting tumor growth both at the time of tumor implantation and once tumors were established. Tumor volume in mice was reduced 25 days after implantation compared to controls in both studies.

[0260] Example 16. CD20xCD3 bispecific antibodies deplete B cell numbers in cynomolgus monkeys and have a pharmacokinetic profile typical of monoclonal antibodies A pilot non-GLP toxicology and pharmacology study was conducted in cynomolgus monkeys (Macaca fascicularis) to determine the ability of the CD3xCD20 bispecific antibody to deplete B cell numbers in these animals. Three cohorts of male animals were organized. Cohort 1 were administered the bispecific antibody BS3 / 20-001 and included three different dose groups (0.01, 0.10, and 1.00 mg / kg), with 3-4 animals per dose group. Cohort 2 was a cohort of two animals that received a low dose of anti-CD20 control antibody (Control V; 0.01 mg / kg). Cohort 3 A cohort of four animals received a high dose of an anti-CD20 control antibody (Control III; 1.0 mg / kg). Blood was collected on day -7 and immediately prior to dosing to establish baseline levels for B and T cells in these animals. Drug doses of 0.01, 0.10, or 1.00 mg / kg were administered by intravenous (iv) infusion, and blood was collected 5 minutes, 5 hours, and 1, 4, 7, and 14 days after dosing. After day 14 post-dose, blood was collected every two weeks until the end of the study. Blood samples were analyzed for B and T cell markers by FACS, and absolute numbers of these cell types were determined. Serum samples were also analyzed for cytokine levels (IFNγ, IL-2, IL-6, and TNFα) using standard analytical methods. The results are shown in Figure 3 (B cells), Figure 4 (T cells), and Figures 5A–5D (cytokines).

[0261] As shown in this example, administration of the CD3xCD20 bispecific antibody resulted in depletion of circulating B cells to baseline levels by the first measured time point (day 1). This depletion was not observed in the control animal cohort. B cell depletion in the bispecific cohort was maintained until week 2 after administration, and B cell levels subsequently gradually recovered in the 0.01 and 0.10 mg / kg dose cohorts until the end of the experiment approximately 11 weeks after administration. However, no recovery of B cell levels was observed in the 1.0 mg / kg cohort throughout the experimental period (week 11). T cell levels were also monitored in this experiment. A transient decrease in circulating T cells was observed in the bispecific cohort on day 1 after dosing. T cell levels returned to baseline levels in these cohorts by day 4 and remained at those baseline levels until the end of the experiment. Furthermore, serum cytokine levels for BS3 / 20-001 at 5 hours demonstrated a dose- and time-dependent response consistent with T cell activation (see Figures 5A-5D).

[0262] Gene expression levels in peripheral blood were also analyzed during this experiment. Blood samples were collected at two pre-dose time points (7 days before dosing and immediately before dosing) and 5, 2, and 3 days after dosing. Samples were obtained from animals 4, 72, 96, and 168 hours after treatment. RNA was isolated from these samples and analyzed by microarray. A significant decrease in gene expression of B cell markers was observed in animals treated with the bispecific antibody when compared with pre-dose levels and gene expression levels from the control group; this effect was similar to that observed in samples obtained from animals treated with 1.0 mg / kg control III (the anti-CD20 antibody corresponding to rituximab). The observed changes in B cell marker expression corresponded to the decrease in B cells detected in the blood of treated animals. Expression of T cell marker genes in samples from animals treated with the CD3xCD20 bispecific antibody showed an initial decrease followed by a recovery to normal levels by the 24-hour time point. Furthermore, genes associated with the inflammatory response showed an initial upregulation in animals in the bispecific cohort, but returned to normal or subnormal levels by 24 hours. Finally, examination of the raw intensity of the CD20 gene expression signal suggests that greater depletion of B cells results from treatment of animals with the CD3xCD20 bispecific antibody than with the control anti-CD20 antibody (see Figure 6 and Table 29).

[0263] [Table 32]

[0264] As shown in Table 29, after 7 days of dosing, the raw intensity of the CD20 signal remained at background levels in all but one of the CD3xCD20 animals, while three of four animals treated with 1 mg / kg Control III showed either negligible or detectable CD20 signal levels.

[0265] In the same experiment, the pharmacokinetic profile of the bispecific antibody (Figure 7) was assessed by obtaining blood samples pre-dose and at 0.083, 5, 24, 48, 72, 168, 336, 504, and 840 hours. Resulting serum samples were analyzed by direct enzyme-linked immunosorbent assay (ELISA) to determine the concentration of total bispecific antibody. Serum total bispecific (BS3 / 20-001) concentration data were analyzed by non-compartmental analysis (Phoenix WinNonLin) to determine pharmacokinetic parameters. Results are shown in Table 30 (AUC = area under the curve vs. time; C max = in the desired matrix (maximum observed concentration of compound).

[0266] [Table 33]

[0267] After a single intravenous dose of 0.01, 0.10, or 1.0 mg / kg of BS3 / 20-001 in cynomolgus monkeys, mean peak concentrations (C max ) was observed at the first sampling time (0.083 hours). 4.42, 289 and 4940 μg * Mean AUC in hours / mL all The values ​​are 0.01, 0. Observed at doses of 1 and 1.0 mg / kg: 442, 2890, and 4940 μg per mg / kg * Dose-normalized AUC values ​​(AUC all / dose) is the plasma exposure (A UC all ) increases in a nonlinear manner with increasing dose. A greater than proportional increase in release was observed with increasing antibody dose, suggesting that BS3 / 20-001 may be undergoing target-mediated clearance. The overall pharmacokinetic profile of BS3 / 20-001 is typical of monoclonal antibodies administered to cynomolgus monkeys.

[0268] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Claims

1. A bispecific antibody that binds to human CD20 and human CD3, comprising a first immunoglobulin heavy chain, a second immunoglobulin heavy chain, and two immunoglobulin light chains, wherein each of the first immunoglobulin heavy chain and the second immunoglobulin heavy chain is paired with one immunoglobulin light chain via a disulfide bond; the first immunoglobulin heavy chain comprises: (i) a heavy chain variable region (HCVR) comprising three complementarity determining regions HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 1284, 1286, and 1288, respectively; and (ii) a heavy chain constant region of a human IgG isotype; the second immunoglobulin heavy chain comprises (i) an HCVR comprising three complementarity determining regions, HCDR1, HCDR2, and HCDR3, comprising the amino acid sequences of SEQ ID NOs: 1244, 1246, and 1248, respectively, and (ii) a heavy chain constant region of a human IgG isotype; 10. The bispecific antibody of claim 9, wherein each of the two immunoglobulin light chains comprises: (i) a light chain variable region (LCVR) comprising three complementarity determining regions LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 1292, 1294, and 1296, respectively; and (ii) a light chain constant region.

2. 2. The bispecific antibody of claim 1 , wherein the HCVR of the first immunoglobulin heavy chain comprises the amino acid sequence of SEQ ID NO: 1250, the HCVR of the second immunoglobulin heavy chain comprises the amino acid sequence of SEQ ID NO: 1242, and the LCVR of each of the two immunoglobulin light chains comprises the amino acid sequence of SEQ ID NO: 1258.

3. 2. The bispecific antibody of claim 1 , wherein the HCVR of the first immunoglobulin heavy chain comprises the amino acid sequence of SEQ ID NO: 1282, the HCVR of the second immunoglobulin heavy chain comprises the amino acid sequence of SEQ ID NO: 1242, and the LCVR of each of the two immunoglobulin light chains comprises the amino acid sequence of SEQ ID NO: 1290.

4. The bispecific antibody of any one of claims 1 to 3, wherein the heavy chain constant regions of the first immunoglobulin heavy chain and the second immunoglobulin heavy chain are of the IgG1 isotype. body.

5. 4. The bispecific antibody of claim 1, wherein the heavy chain constant regions of the first immunoglobulin heavy chain and the second immunoglobulin heavy chain are of the IgG4 isotype.

6. 6. The bispecific antibody of claim 1, consisting of a first immunoglobulin heavy chain, a second immunoglobulin heavy chain, and two immunoglobulin light chains.

7. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1 to 6 and a pharmaceutically acceptable carrier or diluent.

8. The pharmaceutical composition of claim 7 for treating a B-cell cancer in a subject.

9. 9. The pharmaceutical composition of claim 8, wherein the B-cell cancer is selected from the group consisting of follicular lymphoma, B-cell chronic lymphocytic leukemia, B-cell lymphoblastic lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, mantle cell lymphoma, hairy cell leukemia, and Burkitt's lymphoma.

10. The pharmaceutical composition of claim 9, wherein the B-cell cancer is follicular lymphoma.

11. The pharmaceutical composition according to claim 9, wherein the B-cell cancer is diffuse large B-cell lymphoma.

12. The pharmaceutical composition of claim 9, wherein the B-cell cancer is marginal zone lymphoma.

13. The pharmaceutical composition of claim 9, wherein the B-cell cancer is mantle cell lymphoma.

14. The pharmaceutical composition of any one of claims 8 to 13, wherein the subject is suffering from a tumor that is resistant or incompletely responsive to anti-CD20 monospecific therapy alone.

15. 15. The pharmaceutical composition of claim 14, wherein the subject is afflicted with a tumor that is resistant or incompletely responsive to rituximab monotherapy.

16. The pharmaceutical composition according to any one of claims 8 to 13, wherein the subject has received anti-CD20 monospecific antibody therapy at least one day to one year prior to administration of the pharmaceutical composition.

17. 17. The pharmaceutical composition of claim 16, wherein the anti-CD20 monospecific therapy comprises or consists of an anti-CD20 monospecific antibody.

18. 18. The pharmaceutical composition of claim 17, wherein the anti-CD20 monospecific antibody is rituximab.

19. 10. An isolated host cell comprising a first recombinant expression vector encoding a first immunoglobulin heavy chain of any one of claims 1 to 6, a second recombinant expression vector encoding a second immunoglobulin heavy chain of any one of claims 1 to 6, and a third recombinant expression vector encoding an immunoglobulin light chain of any one of claims 1 to 6.

20. A method for producing the bispecific antibody according to any one of claims 1 to 6, comprising: (a) culturing the isolated host cell of claim 19 under conditions that allow for the production of the bispecific antibody; and (b) recovering the bispecific antibody so produced. The above method, comprising:

Images